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Inflammatory bowel diseases (IBD), the main focus of this thesis, refer to a 
disease entity involving both active and chronic inflammation in the gastro-intestinal 
(GI) tract (2-4). This introduction describes IBD in terms of epidemiology, symptoms, 
pathophysiology and current medical treatment strategies. It also elaborates on the 
need for novel treatment options for IBD patients. Furthermore a general introduction 
to gene- and cell therapy options for IBD will be provided (1). 
The focal point in the search for novel treatment options in IBD is tolerance 
induction. This requires an exploration of the different mechanisms by which the 
mucosal immune system maintains unresponsiveness to the antigens in the GI tract. A 
failure of mucosal tolerance leads to destructive immune responses and thereby 
disease activity in IBD patients (2-4). Because regulatory T (Treg) cells are key 
players in tolerance induction and maintenance of immune homeostasis (5;6), novel 
therapeutic approaches based on the properties of Treg cells that could be applicable 
in IBD were explored in the research conducted for this thesis.  
 
1.2 Inflammatory Bowel Diseases (IBD) 
IBD are a group of chronic inflammatory disorders most commonly affecting 
young adults (7;8).  The two clinically defined forms of IBD, Crohn’s disease (CD) 
and ulcerative colitis (UC) are chronic remittent or progressive inflammatory disease 




The incidence and prevalence in IBD differ according to geographical location 
and changes in characteristics of that location. A recent systematic review of the 
literature by the American College of Gastroenterology’s IBD Task Force 
demonstrated a geographical variation in IBD incidence and prevalence (9). This 
systemic review reports a higher incidence of CD in industrialized countries. The 
authors also describe a North-South gradient with a strong correlation between 
degrees latitude and CD incidence when the Western Hemisphere and Western 
Europe were evaluated (9). This North-South gradient also existed when individual 
countries were analyzed as for example CD was less common in the southern United 
States (10) and in the south of France (11). A similar epidemiological pattern was 
demonstrated for UC, although the North–South gradient was not shown to be as 
pronounced as it is for CD (9). 
Molodecky and colleagues set out to establish changes in the worldwide 
incidence and prevalence of UC and CD over time (12). In this systemic review of the 
literature the authors concluded that, although there are few epidemiologic data from 
developing countries, the incidence and prevalence of IBD are going up with time and 
in different regions around the world, indicating that IBD is now surfacing as a global 
disease (12). 
 
1.2.2 Symptoms  
IBD are clinically diagnosed through medical history and physical 
examination, together with results from endoscopic, radiological, laboratory, and 
histological studies (2-4). The distinction between CD and UC is also based on these 
phenotypic criteria, and is not always possible because CD and UC have overlapping 
clinical characteristics (2-4). The peak age of onset for IBD is between 15–30 years, 
although the disease can be diagnosed at any age (8;9).  




CD is a relapsing disease of the gastrointestinal (GI) mucosa that can involve 
the entire GI tract from the mouth to the anus (2-4). Patients often present with 
alternating healthy and diseased portions in the GI tract and the development of 
complications including strictures, abscesses, or fistulas (2-4). Extra-intestinal 
manifestations are common and include ankylosing spondylitis, iritis, uveitis, 
pyoderma gangrenosum and erythema nodosum (13). Additionally a number of 
diseases (asthma, bronchitis, pericarditis, psoriasis, rheumatoid arthritis, and multiple 
sclerosis) are reported in association with CD (13). Pathological features include 
transmural mucosal inflammation in the gut (2-4). A systematic review and meta-
analysis of population-based studies from the period January 1965 to February 2008 
demonstrated that among unselected patients with CD, overall mortality was slightly 
but significantly higher than in the general population (14). These results were 
primarily explained by deaths from GI, respiratory, and genitourinary diseases (14). 
UC is a relapsing non-transmural inflammatory disease that is limited to the 
colon (2-4). Patients characteristically present with bloody diarrhea, passage of pus, 
mucus, or both, and abdominal cramping (2-4). Extra-intestinal manifestations occur 
in 10 to 30 % of patients with UC (15) and can also involve various organs and 
systems (joints, skin, liver, eye, mouth, and coagulation) (15). Pathological features 
include distorted crypt architecture of the epithelial layer of the gut (2-4). Meta-
analysis of population based inception cohort studies from January 1965 through 
March 2006, demonstrated that the overall risk of dying in patients with UC did not 
differ from that of the background population (16). In this meta-analysis, patients with 
newly diagnosed and extensive disease were shown to have a greater risk of dying 
from UC itself or related surgical complications (16). However, the authors suggest 
that this is counterbalanced by a reduced mortality from other causes, as for example 
pulmonary cancer, because patients followed closely by physicians have the 
advantage of early detection and treatment (16).   
IBD are linked to increased incidence and mortality from colorectal 
adenocarcinoma (CRC) (17-19). CRC is promoted by the chronic inflammation, 
intestinal damage, regeneration and repair occurring in both CD and UC (20) and a 
recent study in IBD patients demonstrated that incidence of CRC was 60% higher 
than in the general population (19). 
IBD are associated with a considerable reduction in quality of life of the 
patients (21-23). Anxiety and depression are common in IBD (21). Additionally, 
fatigue and poor sleep are highly prevalent (22).  
 
1.2.3 Pathogenesis 
The pathogenesis of IBD is unknown (2-4). It has been recognized that a 
proportion of the risk to develop IBD is genetically determined and most likely 
involves various defects in the immune system (2-4). The discordance of IBD among 
monozygotic twins (24) and the development of IBD in immigrants to high 
prevalence countries (25) and in countries undergoing westernization also highlights 
the importance of environmental factors in disease pathogenesis (4;26). 
 
  




1.2.4 Medical management 
IBD are managed with medical treatment strategies, although a substantial part 
of the patient population will require surgical intervention at a certain point in time 
(27). Medical therapies for UC and CD include aminosalicylates, corticosteroids, 
thiopurines, methotrexate, and anti-TNF-alpha antibodies (28). Drug type and timing 
are further decided upon and optimized based on the situation of an individual patient 
to manage the disease effectively (28). In that context, the choice of treatment 
depends on disease activity and extent, as well as patient acceptability and mode of 
drug delivery (28).  
Despite state-of-the-art medical treatment, a significant number of IBD 
patients have either persistently active disease or complications that are associated 
with a reduced quality of life and may necessitate surgery (21-23;27;29). For this 
reason, the development of new treatments that prevent initiation of inflammation and 
induce long-term remission, or preferably a cure, is required. 
 




Gene and cell therapy approaches can be applied to prevent inflammation in 
the GI tract. Gene therapy consists of the delivery of a gene or multiple genes to cells 
with the aim of achieving gene expression, thereby offering therapeutic benefit. Cell 
therapy is defined as the infusion or transplantation of cells into a patient for the 
treatment or prevention of disease. Both approaches have been applied successfully in 
clinical trials for a broad range of diseases, including promising early stage clinical 
development for IBD (30-40).  
 
1.3.2 Gene therapy as treatment for IBD 
To facilitate the uptake of the DNA construct and the expression of the 
transgene in the target cell, a vector is required. Vectors can be non-viral or viral. The 
choice of a safe and reliable vector that can mediate long-term gene transfer to both 
dividing and non-dividing cells is of vital importance for a gene therapy approach. 
Although viral vectors are often created from pathogenic viruses, they are always 
manipulated in order to render them harmless. This often involves the deletion of a 
part of the viral genome critical for viral replication. Such a modified virus can 
efficiently infect cells and has the potential for long term stable gene expression, but 
has lost the capability to replicate. The gene therapy section of this chapter will focus 
on viral vectors that have been used successfully in gene therapy applications in 
recent years (31;32), are able to target the gut (41-49) and can therefore be considered 
as vectors capable of gene delivery in the GI tract (for an overview see: Table 1.1 or 
Figure 1.1). 
For an overview of non-viral delivery methods to the intestine the review from 
O’Neill et al. is recommended (50).  




1.3.2.1 Retroviral vectors  
 Retroviral vectors were first clinically used more than twenty years ago (51-
53) and for a long period remained the most commonly used vectors in gene therapy. 
Retroviral particles require disruption of the nuclear membrane to gain access and 
therefore are dependent on cell division for entering the cell (54). Retroviruses can 
transduce intestinal epithelial cells (41-43), although at a low efficiency. Retroviruses 
can be further subdivided in the Moloney murine leukemia virus (MMLV) and the 
lentiviruses. 
 Intestinal epithelial cells can be transduced much more efficiently by 
lentiviruses (44). The lentiviruses have a major advantage over MMLV for gene 
therapy as they have the ability to transduce non-dividing cells (55;56). Furthermore 
lentivirus does not induce mucosal damage or distribute beyond the distal colon (44) 
and appeared therefore as a potential vector for gene delivery in the treatment of IBD.  
 An important safety issue to be considered with both MMLV- and lentiviral 
vectors is their potential to integrate at many sites in the human genome (57-59). 
Those genomic integrations can result in insertional mutagenesis causing cancer 
development as has been observed in clinical trials (36;60-62) and even though 
significant improvements in lentiviral vector safety have been achieved in recent 
years (63), these concerns need to be addressed (64;65) before these vectors can be 
considered as safe tools for gene therapy applications in IBD. 
 
1.3.2.2 Adenoviral vectors  
Despite the fact that adenoviruses are pathogenic viruses that cause morbidity, 
especially in immune-compromised patients (66), adenoviral vectors have been 
frequently used in gene therapy due to their broad tissue tropism and lack of 
integration into the host genome (67). Gene therapy using adenoviral vectors has 
shown potential in the treatment of colitis in preclinical models (45-47). A single 
systemic injection of an adenoviral vector carrying the anti-inflammatory cytokine 
interleukin-10 (IL-10) transgene was sufficient not only to prevent the onset of colitis 
but also to induce clinical and histological remission in mice with established disease 
(46). Additionally Schmiedlin-Ren and colleagues demonstrated that intestinal 
epithelial cells of IBD patients can be efficiently transduced ex vivo by adenoviral 
vectors (68). All together, these results suggest that targeting genes to inflamed 
intestine through the luminal route can be possible using adenoviral vectors (68). 
However, hematologic and hepatic toxicities were observed in animal studies 
after injection with high vector doses (69-71), which imply that further development 
in generating a new type of adenoviral vector is necessary before to consider clinical 
applications. Recently a gutted adenovirus, devoid of all viral coding sequences, was 
shown to induce less toxicity (72) after delivery. However, this finding, if promising 
for future therapeutic applications, needs further exploration.  
  




1.3.2.3 Adeno-associated viral vector 
The non-pathogenic, replication-deficient adeno-associated virus (AAV) has 
become the gene therapy vector of choice for in vivo applications. AAV vectors have 
a good safety profile as it remains predominantly episomal (73): 99% of recombinant 
AAV are maintained as episomal copies (74), indicating a very low risk of insertional 
mutagenesis compared to retroviral vectors. Furthermore, AAV vectors are able to 
transduce both dividing and quiescent cells (75;76) and were demonstrated to be 
effective as gene therapy vectors in several preclinical models for autoimmune- and 
inflammatory disorders (77-84). The therapeutic potential of AAV as a vector in gene 
therapy has also been demonstrated in a clinical setting in recent studies (85-95), 
leading to the market authorization of one product (Alipogene tiparvovec, Glybera®) 
in Europe. 
AAV vectors can target the GI tract (48;49) and long term transgene 
expression post AAV treatment was reported which in relation with the high turn-over 
of intestinal cells, suggests that transduction of the slow-dividing intestinal stem cells 
was achieved (48;49). Additionally Polyak and colleagues have recently demonstrated 
that mice, in an experimental model of IBD treated with an AAV vector carrying the 
IL-10 transgene, had lower disease activity index scores and lower inflammation 
scores, thereby confirming the potential of AAV vector based treatment strategies for 
IBD (96). 
 
1.3.3 Cell therapy as treatment for IBD 
Cell-based therapies aim to introduce new cells into a tissue in order to treat a 
disease and can permit the replacement of function (97), or restore the homeostasis of 
the immune system (98). In the last 50 years hematopoietic stem cell transplantation 
as a curative option for inherited disorders has been developed (30;99), leading the 
way toward innovative therapies for other illnesses. Recent results obtained from 
animal models and early human clinical trials in graft versus host disease but also CD 
showed that either regulatory T lymphocytes or mesenchymal stromal cells may be of 
clinical relevance for the treatment of IBD (for an overview see: Table 1.1 or Figure 
1.1). 
 
1.3.3.1 Regulatory T lymphocytes  
The immune system contains a population of T cells, designated regulatory T 
lymphocytes that are specialized in immune suppression (5;100). Low-level 
autoimmunity seems relatively common in the intestine as a result of the presence of 
the microbial flora or auto-reactive T cells. Under physiological circumstances 
regulatory T lymphocytes are generated in the mesenteric lymph nodes, followed by 
migration and subsequent expansion in the gut (101), thereby preventing progress to 
chronic autoimmune disease (102;103). These cells are able to suppress an immune 
response both by cell contact (e.g. killing or functional modulation of antigen 
presenting cells or effector T cells) and soluble factor-dependent mechanisms (e.g. 
secretion of immunosuppressive cytokines or deprivation of cytokines necessary for 
the expansion/survival of responder T cells) (104;105). Regulatory T lymphocytes 
were shown to be effective in both the cure and the prevention of experimental colitis 
in multiple animal models (106). For example, transfer of regulatory T lymphocytes 
to colitic mice led to resolution of the lamina propria infiltrate in the intestine and 
reappearance of normal intestinal architecture (107).  
Among the different T cells with suppressive activity the 
CD4+CD25highFOXP3+ regulatory T (Treg) cell (5) and the type 1 regulatory T (Tr1) 
cell (100) subsets are the most well-defined to date. The Tr1 cell is typically 




characterized based on the cytokine production profile (IL-10high) (100) and Treg cells 
by the expression of the transcription factor Forkhead box p3 (FOXP3 in 
humans/Foxp3 in mice), which appears to function as the master regulator in their 
development and function (108;109). Both subsets were shown to be effective in 
preclinical models for the treatment of IBD and both were applied in phase I clinical 
trials. 
Treg cells were shown to prevent and cure experimental colitis (106;107) and 
have been found to be safe in the treatment of acute graft versus host disease in phase 
I clinical trials (38;110). Tr1 cells were shown to have the potential to prevent and 
cure colitis in experimental mice models of IBD (106;111;112) and a preliminary 
efficacy signal in patients was reported in a phase I and a phase I/II trial for refractory 
CD (113;114). Currently the efficacy of Treg cell and Tr1 cell based cell therapy 
awaits further confirmation from phase II/III clinical trials but overall these results 
emphasize that both Treg cells and Tr1 cells are promising tools for therapeutic 
applications in IBD. 
 
1.3.3.2 Mesenchymal stromal cells  
Mesenchymal stromal cells (MSCs) are non-hematopoietic stromal cells 
exhibiting multi-lineage differentiation capacity and the ability to mediate 
immunosuppressive and anti-inflammatory effects (115-118). The mechanism by 
which MSCs suppress the immune system is not fully understood. It is known 
however that MSCs have immunosuppressive features in common with regulatory T 
lymphocytes, including prevention of the maturation of antigen presenting cells 
(APCs) (115) and physically hindering T cells from contacting APCs (116). 
Additionally it was shown that FOXP3 expression confers a greater 
immunosuppressive potential to MSCs (119).  
MSCs can be isolated from various tissues (120-122) and systemic infusion 
was shown to ameliorate experimental colitis (123;124). In humans MSCs obtained 
from adipose tissue induced healing in perianal fistulas in patients with CD (34). 
Furthermore, it was recently shown that MSCs derived from the bone marrow of 
refractory CD patients have identical characteristics compared to MSCs from healthy 
donors and have intact immunomodulatory capacities in vitro (39). In a phase I trial 
administration of autologous bone marrow-derived MSCs was shown to be safe and 
feasible in the treatment of refractory CD (39). Additionally it was demonstrated that 
ex vivo expanded autologous bone marrow-derived MSCs are a safe and feasible 
approach for intrafistular injections in patients with CD (40). These results (34;39;40) 
are exciting, but await further confirmation in phase II/III clinical trials that are 
currently under way. 
 
1.3.4 Can gene and cell therapy be combined in the treatment of IBD? 
The phenotype and function of lymphocytes can be modified using viral 
vectors, creating tools for a cell therapy approach in the treatment of autoimmune, and 
inflammatory disorders (125) and by consequent IBD (126-129).  
Targeting ex vivo, spleen derived CD4+ T cells by a retroviral vector 
containing IL-10 as a transgene generated Tr1 cells that prevented colitis in an 
experimental model of IBD (126). Transduction of T cells using Foxp3 as a transgene 
is sufficient to reprogram them to fully functional Treg cells, which suppress 
autoimmunity and graft rejection in vivo (128;130-132). Furthermore, Hori and 
colleagues showed that such Treg cells prevented colitis in a mice model of IBD 
(128). Additionally Treg cells can be efficiently transduced to express functional 
antigen-specific receptors (129). Adoptive transfer of small numbers of these 




transduced Treg cells was associated with antigen-specific, dose-dependent 
amelioration of experimental colitis in mice (129). 
 
1.3.5 General considerations relevant for IBD 
The route of therapeutic delivery is important when considering gene or cell 
therapy in relation with IBD. The mucus lining in the intestine is a barrier for gene 
transfer via the luminal route (133) and the clearance of viral particles by the liver 
represents a problem for the systemic delivery (134). Nonetheless, as previously 
mentioned, it has been shown that transduction via these routes is possible and that 
long term transgene expression can be achieved. Although viral vectors, for example 
the AAV based vectors, can transduce the GI tract, it seems that gene targeting to the 
gut needs to be further optimized. This could be achieved by testing different existing 
serotypes (135) or modifying the AAV capsid (136). A promising method is the so 
called DNA shuffling, combining useful mutations from individual genes allowing for 
the development of cell type-specific vectors (136;137). Furthermore chemical 
redirection of the AAV capsid shows potential in engineering vectors with novel 
tissue tropisms (138).  
Due to the presence of stem cells in the intestinal crypts (139) the gut is 
suggested to be an interesting target for therapeutic gene transfer. Each crypt in the 
intestine harbors four to six individual stem cells (139). Because stem cells are 
believed to divide very rarely (139) these cells have the potential to permit long term, 
stable transgene expression after transduction. It has been shown that intestinal stem 
cells can be transduced in vitro using a retroviral vector (140) and long-term 
transgene expression observed in the gut after AAV vector delivery in mice suggests 
that transduction of intestinal stem cells is possible in vivo (48;49).  
Antigen-specific Treg cells have been reported to be therapeutically more 
effective than non-selected polyclonal Treg cells (131;141;142). In most models of 
autoimmune diseases, the antigens that induce T cell activation are known, allowing 
generation of, antigen-specific Treg cells that are able to potently suppress activation 
in an antigen dependent manner (143). Unfortunately, in IBD the antigenic targets are 
not definitively defined (4) and strategies using Treg based cell therapy have to be 
restricted to polyclonal Treg cells. This is not a limitation since Treg cells do not need 
to be antigen specific in order to suppress immune responses as a result of bystander 
suppression and infectious tolerance (143;144). Bystander suppression refers to the 
phenomenon that Treg cells with one antigen specificity can suppress effector T cells 
with many other distinct antigen specificities (143;144). Infectious tolerance is the 
occurrence that one population of Treg cells in vivo creates a regulatory milieu that 
promotes the outgrowth of a new population of Treg cells with antigen specificities 
distinct from those of the original population (144;145).  
 
1.3.6 Concluding remarks 
IBD are a group of chronic inflammatory disorders most commonly affecting 
young adults that currently cannot be cured. A gene therapy approach for the local 
expression of therapeutic agents in the gut or a cell therapy approach using regulatory 
T cells or mesenchymal stromal cells may offer an alternative treatment for GI 
inflammation. Both gene and cell therapy approaches have shown promising results in 
preclinical models of IBD. Cell therapies approaches have been translated to the clinic 
and currently phase II/III clinical trials for the treatment of refractory CD are in 
progress. Concerning gene therapy, further development of viral vector delivery to the 
gut is needed and long term efficacy still has to be demonstrated, but pre-clinical data 
are promising. 




Overall, both cell therapy and gene therapy have the potential to become 
important players in the next generation of therapeutic agents that will be aimed at 
unmet medical needs as those that exist in IBD. 
 
1.4 Regulatory T cells for clinical applications in IBD: in vitro versus in vivo 
strategies 
The cell therapy section of this thesis is focused on the development of a new, 
straightforward protocol to generate sufficient numbers of inducible Treg cells in vitro 
for future treatment of IBD. The gene therapy section is focused on the adeno-
associated viral (AAV) vector mediated delivery of immunomodulatory peptides for 
in vivo Treg cell activation and induction in the treatment of IBD. 
 
1.4.1 In vitro generated regulatory T cells for the treatment of IBD 
The CD4+CD25highFOXP3+ regulatory T (Treg) cells (5), as discussed in part 
1.3.3.1 of this introduction can be further sub-divided in two populations according to 
their thymic (nTreg cells) or peripheral (iTreg cells) origin. Both cellular subtypes 
show potential as therapeutic agent for treatment of IBD. 
nTreg and iTreg occupy distinct niches in the immune system (146;147) and 
exert specialized regulatory functions in immune homeostasis (147). It was recently 
demonstrated that mice deficient in iTreg cells spontaneously developed pathologies 
at mucosal sites (148) but that nTreg cells appear sufficient for control of systemic 
and tissue-specific autoimmunity (148). Thus both iTreg and nTreg are required to 
maintain the immune homeostasis, supporting a division of labor in the immune 
system under normal circumstances (6;148;149). 
nTreg cell selection takes place in the thymus and is instructed by T cell 
receptors (TCRs) with affinity for self-peptide major histocompatibility complex 
(MHC) ligands (148). Therefore nTreg cells are specific for self-antigen. iTreg cell 
are induced cells originating from naive T cells in the periphery (6). This induction 
takes place either by naive T cell activation in the absence of inflammation or in 
inflammatory conditions that allow for the development of both iTreg and T effector 
cells in inflammatory sites (6;150). Therefore iTreg cells have TCRs that recognize 
antigens to which an organism is chronically exposed under homeostatic, non-
inflammatory conditions, such as those derived from the commensal microbiota or 
environmental antigens (148). 
In Phase I clinical trials a favorable safety profile was shown for nTreg cells in 
the treatment of acute graft versus host disease (38;110). A shortcoming to the use of 
nTreg cells in the clinic is the limited number of these regulatory cells as they 
constitute only 1-2 % of the peripheral CD4+ T cell population in humans. In an 
attempt to over-come this limitation, several groups have reported different methods 
to expand functional nTreg cells (110;151). However, it was recently reported that 
cellular therapy using iTreg cells has potential advantages over cellular therapy using 
nTreg cells (152;153). These advantages include the potential of generating large 
numbers of cells thereby, reducing production costs (152;153). Additionally, nTreg 
cells are –by definition- specific for self-antigen and might lack potency towards 
immune responses directed to the foreign antigens present in the gut. Therefore, iTreg 
cells seem to be the preferred cell type for therapeutic application in IBD, potentially 
in combination with nTreg.  
 
1.4.2 In vivo induction of regulatory T cells for the treatment of IBD 
Biological therapies that target immune pathways have emerged as new 
therapeutic approaches for the treatment of immune-mediated diseases. They include 




administration of monoclonal antibodies against inflammatory cytokines (154) and 
those that influence immune responses such as small molecules with anti-
inflammatory properties, Helminths derived proteins and stem cells (1;155;156). As 
IBD is an immune-mediated disease, these biological therapies are highly promising 
treatment approaches and have the potential to achieve mucosal tolerance and long 
term remission in IBD (1;154-156). However, the use of immunomodulatory peptides 
in clinical applications for IBD so far have shown that the in vivo delivery of these 
peptides for therapeutic purposes is hindered by difficulties in obtaining sufficient and 
stable peptide concentrations (157-159). Therefore, novel means for stable delivery of 
regulatory peptides have to be explored.  
 
1.4.3 Adeno-associated viral vector based gene therapy for the delivery of 
immunomodulatory peptides 
Adeno-associated viruses (AAV) based vectors are currently, as discussed in 
part 1.3.2.3 of this introduction the safest and most promising viral vectors for in vivo 
gene transfer into post-mitotic tissues (87-92;94;160-162). 
Therefore AAV was chosen as a vector for in vivo gene transfer approaches in 
this thesis. AAV vector based therapy and its possible application in IBD will be 
discussed in more detail in this part of the introduction.  
 
1.4.3.1 AAV vectors in gene therapy 
AAV have a number of attractive features as gene delivery vehicles (135;160). 
As a viral vector it has tropism for different tissues and cell types and long-term 
expression can be achieved in the absence of integration in the host genome 
(135;160). Wild-type AAV is not associated with any known illness (135;160), is 
naturally replication-defective and can replicate only in the presence of a helper virus, 
such as adenovirus or herpes simplex virus (135;160). Although genetic diseases are 
the foremost promising targets for clinical applications (160), several clinical trials for 
acquired diseases have been undertaken using the AAV as a vector, i.e. severe heart 
failure (Phase I/II clinical trial) (93), Parkinson’s disease (Phase I/II) (87;163-167) 
and Rheumatoid arthritis (Phase I) (168;169).  
 
1.4.3.2 Humoral immune responses to the AAV vector capsid 
A potential barrier to the use of AAV vectors in gene therapy applications are 
pre-existing neutralizing antibodies (nAb), which have been associated with a partial 
to complete block of transduction (170-174). These antibodies are formed either after 
treatment with an AAV vector in a gene therapy based approach, preventing re-
administration, or after exposure to the wild-type virus in the general population (170-
174).  
The prevalence of nAb against the different AAV serotypes in IBD patients is 
not known. A lower prevalence of nAb against certain serotypes may be expected, as 
compared to the healthy population given the immune system suppressing drugs taken 
by IBD patients. Furthermore, it is known that IBD patients mount less of a humoral 
immune response after tetanus toxin immunization, suggesting the presence of 
humoral immune defects in IBD (175). Additionally, differences in these humoral 
immune defects exist between CD and UC (2-4).  
 
1.4.3.3 Strategies for modulating the humoral immune response to the AAV vector 
capsid 
Targeted immunosuppressive treatment can deplete or prevent the formation 
of plasma B cells producing antibodies against the AAV vector capsid. This approach 




could permit re-administration or treatment in patients who were previously exposed 
to wild type AAV. The approaches considered are discussed in Table 1.2. Different 
immunosuppressive drugs in the context of AAV vector based gene therapy have been 
explored in a pre-clinical setting.  
Bortezomib, an inhibitor of the 26S proteasome (176;177) significantly 
depleted AAV-specific plasma cells in secondary lymphoid organs and bone marrow 
after AAV vector based gene therapy in mice (178). However, the inhibition of the 
immune response by bortezomib was insufficient to allow subsequent re-infection 
with a recombinant AAV vector of a similar serotype in this particular experimental 
set-up (178). The authors suggested that this shortcoming is probably due to the 
combination of residual antibody levels and the inability of bortezomib to completely 
deplete the memory B cells that are re-activated in response to a repeated infection 
with a recombinant AAV vector in this particular experimental set-up (178).  
CD20 is a B-cell surface marker that is expressed on pre-B cells, mature B 
cells and memory B cells (179;180). Anti-CD monoclonal antibodies have three 
different mechanisms of action: antibody-dependent cell cytotoxicity, complement-
dependent cell killing, and induction of apoptotic cell death (179;180), overall leading 
to a decrease in antibody production. The immune response against the AAV capsid 
was ameliorated after treatment with an anti-CD20 monoclonal antibody (181-184). 
In non-human primates treated with an AAV vector, anti-AAV humoral responses 
were attenuated during 12 weeks, when treated with a combination of Mycophenolate 
Mofetil, anti-thymocyte immunoglobulin, methylprednisolone, tacrolimus and anti-
CD20 (183). However, anti-AAV humoral responses resurfaced when this 
immunosuppressive regimen was stopped, which made subsequent gene transfer with 
an AAV vector impossible (183). In a different experiment in non-human primates, a 
short course of immune-suppression with only anti-CD20 was shown to be safe (182). 
Furthermore in one animal, following anti-CD20 treatment, anti-AAV antibodies 
declined which permitted AAV vector readministration (182).  
Overall it is of importance to search for an immunosuppressive strategy which 
comprises a short time interval and at the lowest dose possible, thereby minimizing 
the side effects for the patients, but still allowing for a therapeutic window of 
opportunity for efficient AAV vector administration. Immunosuppressive strategies 
that target both plasma cells and memory B cells for the transient elimination of 
immunity against AAV vectors could be effective (178) and should be further 
explored. 
  




1.5 Outline of the thesis 
The availability of an expanding number of evidence based, novel therapeutics 
such as anti-TNF-alfa antibodies has set the bar high for the development of gene and 
cell based treatment approaches (185). However a substantial portion of patients does 
not respond to anti-TNF-alfa antibodies or lose their initial response to treatment 
(186;187). For CD, only 10% of the patients have prolonged clinical remission (186). 
Additionally, more recently applied pro-inflammatory cytokine blocking agents, as 
for example anti-IL-17 have been unsuccessful in the treatment of CD (188). 
Therefore, development of new treatment strategies to prevent initiation of 
inflammation and allow for long-term remission is required, especially for those 
patients who do not respond to the currently available medications for IBD.  
 
1.5.1 Cell therapy based treatment strategies for IBD 
It is unknown how Treg cells can be best applied as a cell therapy based 
treatment for IBD and novel strategies are needed to generate stable iTreg cells in 
vitro for this purpose. Chapter 2 describes a novel, two-step naive T cell activation 
protocol by which in vitro, within 4 days iTreg cells are generated. The phenotype and 
functionality of those cells were assessed by flow cytometry and MLRs and were 
shown to be sustainable over a period of at least 30 days in culture. These cells could 
be used either alone or together with nTreg cells in the treatment of IBD. Chapter 3 
demonstrates that the iTreg cells generated in vitro by the two-step naive T cell 
activation protocol are able to ameliorate experimental colitis in vivo.  
 
1.5.2 Gene therapy based treatment strategies for IBD 
In relation with AAV based gene therapies, the prevalence of nAbs against the 
AAV capsid has to be explored in IBD patients and strategies aiming to decrease the 
pre-existing humoral immunity need to be investigated. The work done in Part 2 of 
the thesis has focused on these topics. Chapter 4 describes a study in which 
circulating nAbs against the AAV serotypes 1, 2, 3, 4, 5, 6 and 8 were measured using 
a previously established virus neutralization assay. 100 healthy donors and 200 IBD 
patient’s serum samples (101 CD and 99 UC) were analyzed. This study establishes a 
foundation for the development of an AAV based gene therapy approach as a novel 
treatment for IBD. Chapter 5 describes the use of AAV5 mediated delivery of 
regulatory T-cell epitopes as therapeutic approach for treatment of IBD. Chapter 6 
deals with the exploration of the role of pre-existing nAbs on AAV transduction in 
vivo. For this purpose an experimental model for in vivo passive transfer of plasma 
containing defined titer of anti-AAV nAbs was established. Chapter 7 describes the 
use of immunosuppressive regimens to reduce humoral immunogenicity generated by 
primary AAV vector gene delivery.  
 
1.5.3 Discussion, conclusions and future prospects   
Chapter 8 provides a summarizing discussion on the research performed for 
this thesis, including future prospects and plans. 
  





Figure 1.1 Overview of the gene and cell therapy based treatment 
strategies for inflammatory bowel diseases (IBD) as discussed in Chapter 1.  
AAV, adeno-, associated virus; N/A, not applicable; Treg cell, 
CD4+CD25highFOXP3+ regulatory T cell; Tr1 cell, type 1 regulatory T cell. 
  





strategy Subclass Strategy specific characteristics (pre-) Clinical 
Development for 
application in IBD 









Reference for gut 
targeting 
Retro- and 
lentiviral Yes (41-44) Not performed N/A 
Adenoviral Yes (45-47) Animal models (45-47) 




Cell type Generated from 
Reference for 
generating cell type 
(pre-) Clinical 
Development 
Reference for (pre-) 
clinical development 
Treg cells Peripheral blood (38;110;152;189;19) Animal models (106;107) 
Tr1 cells Peripheral blood (106;191) 







(34;39;40) Phase I clinical trials (34;39;40) 
 
C. 
















transduction (126;128) Animal models (126;128) 




transduction (129) Animal models (129) 
 
 
Table 1.1 Overview of the gene and cell therapy based treatment strategies for IBD as 
discussed in Chapter 1. The status of development refers to research which has 
already been performed. 
AAV, adeno-, associated virus; N/A, not applicable; Treg cell, 
CD4+CD25highFOXP3+ regulatory T cell; Tr1 cell, type 1 regulatory T cell. 
  




Proposed strategy Proposed treatment Remarks in the context of AAV vector based gene therapy 
Anti antibody therapy: remove or 
neutralize antibodies 
Remove antibody: plasmapheresis 
After 6-8 hours rebound antibody in the 
circulation, therefore narrow window of 
opportunity for AAV vector based gene 
therapy 
Neutralize antibody: intravenous 
immunoglobulins (IVIG) 
Proposed dosing 1-2g/kg, 2-5 days prior to 
AAV treatment 
Anti lymphocyte therapy: targeting both 
B cells and T (helper) cell populations, 
thereby causing B-cell toxicity, 
apoptosis or inhibition of proliferation 
and modulation of the antibody 
production 
Thymoglobulin Proposed dosing 3-4 doses to a cumulative dose of 6mg/kg  prior to AAV treatment 
Azathioprine Proposed dosing 1-3mg/kg/day prior to AAV treatment. 
Anti complement therapy: blocking the 
activation of terminal complement, 
which is implicated in the humoral 
immune response 
Anti-complement protein C5  monoclonal 
antibody (Eculizumab) 
Proposed dosing 600mg for 5 weeks prior 
to AAV treatment 
Anti plasma-cell therapy: using 
proteasome inhibition, which causes 
apoptosis of normal plasma cells and 
modulation of the antibody production 
Proteasome inhibitors (Bortezomib) Promising in combination with  Anti-CD20 monoclonal antibody 
Anti pre B-cell, mature B-cell and 
memory B-cell therapy: overall leading 
to a decrease in antibody production 
Anti-CD20 monoclonal antibody 
(Rituximab) 




Table 1.2 Options for targeting neutralizing antibodies against the AAV capsid, 
prior to AAV based gene therapy applications. The proposed treatment strategies 
could be applied either alone as mono-therapy or combining different approaches. 









Chapter 2 Generation of stable, functional regulatory T lymphocytes in vitro 
within 4 days by a two-step activation protocol 
 
2.1 Introduction 
2.2 Material and methods 
2.2.1 Samples 
2.2.2 Isolation and stimulation of CD4+CD25- T cells  
2.2.3 Phenotypical characterization  
2.2.4 Viability and proliferation 
2.2.5 Functional characterization 
2.3 Results 
2.3.1 Induction of a regulatory phenotype in CD4+CD25- T cells     
2.3.2 TregPMA cells suppress the proliferation of responder cells in vitro  
2.3.3 Phenotype and function of TregPMA cells are stable in long term culture 
2.3.4 Phenotype and function of TregPMA cells are stable in long term culture 
2.3.4.1 Expression of regulatory markers after long term culture 
2.3.4.2 Stable regulatory function of the TregPMA cells after 30 days 
in culture 
2.4 Discussion 
2.5 Conclusions  
 





Regulatory T (Treg) cells are key players in maintaining peripheral tolerance, 
preventing autoimmune diseases and limiting chronic inflammation (5). Therefore, 
strategies that aim for therapeutic tolerance induction may take advantage of the 
functions of Treg cells (192). 
The transcription factor FOXP3 is generally considered as the master regulator 
in the development and function of Treg cells (108;109;128). However FOXP3 
expression can also be induced in human T effector cells which do not have 
suppressive activity (193). Thus, FOXP3 expression is necessary, but not sufficient to 
identify functional Treg cells and other markers have to be taken in consideration as 
well (193).  
Treg cells are able to suppress an immune response both by cell contact (e.g. 
killing or functional modulation of antigen presenting cells or effector T cells) and 
soluble factor dependent mechanisms (e.g. secretion of immunosuppressive cytokines 
or deprivation of cytokines necessary for the expansion/survival of responder T cells) 
(105). They are considered to be an attractive tool for the treatment of a broad range 
of diseases (194-198). Recently, different groups have been able to expand functional, 
naturally occurring regulatory T (nTreg) cells ex vivo (152;189;190). In Phase I 
clinical trials a favourable safety profile was shown for nTreg cells in the treatment of 
acute graft versus host disease (38;110). However it was reported by the same group 
(153) that ‘cellular therapy using Treg cells induced in vitro has several potential 
advantages over nTreg cells, including ease of isolation, increased number of the 
starting population, greater proliferation potential and reduced production costs’ 
(152). Additionally multiple defects in nTreg cells in patients with autoimmune 
diseases have been described (199) which could prevent the use of these cells for the 
treatment of autoimmunity. This problem could be overcome by using Treg cells 
induced in vitro. These induced Treg (iTreg) cells like nTreg cells, have been shown 
to suppress auto-, and allo-reactivity in vivo (153;200). Furthermore, it has been 
demonstrated that the physiologic generation of iTreg cells from naive T cells in vivo, 
is essential for establishing oral tolerance (201) and that iTreg cells generated in vitro 
can act in synergy with nTreg cells from the same donor to restore and maintain 
tolerance in vivo (202). It is therefore postulated that iTreg cells could have an 
important, non-redundant role in establishing tolerance (201-203). Consequently 
iTreg cells generated from CD4+CD25- T cells in vitro have potential, either alone or 
together with nTreg cells, for the treatment of allergy, autoimmune or inflammatory 
disorders.  
This approach has been explored before, whereby stimulation with anti-CD3 
was an important element (204;205), as anti-CD3 up-regulates FOXP3 expression in 
vitro (206). However, in contrast to nTreg cells FOXP3 expression seems to decline 
over time in iTreg cells (206) resulting in a loss of regulatory function. Apart from 
activation with anti-CD3 (204;205), several other groups have used different 
strategies to generate iTreg cells in vitro, including use of TGF-beta, all-trans-retinoic 
acid and the recently discovered regulatory cytokine Interleukin-35 (IL-35) (207;208). 
All these technologies require more or less extensive cell handling and processing and 
it remains uncertain whether these methods will enable generation of sufficient iTreg 
cells under Good Manufacturing Practices (GMP). 
We have established a new, simple and robust method to generate stable and 
functional iTreg cells from human CD4+CD25- T cells in vitro. This method is 
composed of two steps of activation with an initial PMA/ionomycin activation step 
followed by anti-CD3 stimulation in presence of a low dose of Interleukin-2 (IL-2). 
This approach has the advantage of promoting the conversion of CD4+CD25- T cells 




to functional iTreg cells and could be suitable for application under GMP. 
Furthermore, by making use of substances that are well known, simple to obtain and 
relatively low priced this protocol could be easy to employ in a routine laboratory 
setting. 
 
2.2 Material and methods  
 
2.2.1 Samples 
Buffy Coats from healthy adults were obtained from the blood bank (Sanquin, 
the Netherlands). The study was reviewed and approved by the ethical board of 
Sanquin Blood Supply Foundation, the Netherlands. Peripheral Blood Mononuclear 
Cells (PBMCs) were extracted using cell preparation tubes with sodium citrate (BD 
Vacutainer® CPT™, BD Biosciences). 
 
2.2.2 Isolation and stimulation of CD4+CD25- T cells  
CD4+CD25- T cells were obtained from PBMC’s by means of negative 
selection using the naive CD4+ T cells isolation kit (Miltenyi Biotec®) and CD25 
microbeads (Miltenyi Biotec®) for additional CD25 depletion to ensure that no 
CD4+CD25+ cells remained, as described before (209). Both isolation steps were 
performed according to the instructions of the manufacturer with the use of LD 
columns (Miltenyi Biotec®). Routine evaluation of the obtained CD4+CD25- 
population analyzed by flow cytometry showed a purity of >95%.  
CD4+CD25- T cells were re-suspended in X-vivo15 human medium (Lonza) 
containing 5% human serum (Lonza) at 2.5x105 cells/ml and subsequently activated 
with PMA (10 ng/ml, obtained from Sigma-Aldrich) and ionomycin (250 ng/ml, 
obtained from Sigma-Aldrich). After 48 hours cells were washed twice with PBS, re-
suspended in medium and activated with 10 μg/ml anti-human CD3 (Clone OKT3, 
eBioscience) in the presence or absence of IL-2 (50 U/ml, obtained from 
eBioscience). Cells were cultured in 96 well, flat bottom plates. IL-2 (50 U/ml) was 
added every 72 hours.  
 
2.2.3 Phenotypical characterization  
Cells were analyzed using flow cytometry (FACSCalibur, BD Biosciences) 
and data analyzed using CellQuest Pro software (BD Biosciences). For Treg cell 
staining the human regulatory T cell staining kit was used (PE-conjugated FOXP3, 
clone PCH101, FITC-conjugated CD4, clone RPA-T4 and APC-conjugated CD25, 
clone BC96) obtained from eBioscience. To assess the specificity of the PCH101 
clone we performed FOXP3 staining with clone PCH101 (eBioscience), 259D/C7 
(BD biosciences) and 3G3 (Miltenyi Biotec®) in parallel, according to the 
instructions of the manufacturer (experiments in triplicate, N=2, data not shown). 
Overall little (<5%), non-significant differences were observed in our experimental 
setup and therefore we continued with PCH101 as this clone has been validated for 
FOXP3 detection (210). 
Additional monoclonal anti-human antibodies used in this study were as 
follows: anti-CD127 (PerCP Cy5.5-conjugated, clone eBioRDR5), anti-CD4 (PE-
conjugated, clone RPA-T4), anti-CD152 (CTLA-4, PE-conjugated, clone 14D3), anti-
AITR/GITR (PE-conjugated, clone eBioAITR), anti-OX40 (CD134, FITC-
conjugated, clone ACT35), anti-ICOS (APC-conjugated, clone ISA-3) and anti-IL-10 
(APC-conjugated, clone JES3-9D7) obtained from eBioscience. The viability dye 7-
AAD (BD Biosciences) and the scatter dot plot were used to exclude dead cells from 
analysis. For intracellular staining (FOXP3, CTLA-4 and IL-10), cells were fixated 




and permeabilized using the FOXP3 staining buffer set from eBioscience. The IL-10 
staining was performed intracellular, as it has been described before (209). High 
expression of a marker is defined as fluorescence intensity greater than 100, as it has 
been described before (211). Regulatory markers were followed over time up until 30 
days in culture, with or without supplementation of a low dose of IL-2 (50 U/ml, 
every 72 hours). As control, CD4+CD25- T cells activated with PMA (10 
ng/ml)/ionomycin (250 ng/ml) followed by IL-2 (50 U/ml) or anti-CD3 (10 μg/ml) 
followed by IL-2 (50 U/ml) were analyzed by flow cytometry after 9 days or after 30 
days in culture.  
 
2.2.4 Viability and proliferation 
Viability of the cells was determined by staining with 7-AAD (BD 
Biosciences) followed by flow cytometry analysis. Cell number was determined by 
use of the NucleoCounter to assess proliferation rate in culture (NucleoCounter, 
Chemometec). 
 
2.2.5 Functional characterization 
Regulatory function was analyzed using Mixed Leukocyte Reactions (MLRs) 
with CFSE stained responder cells (212), described previously as a valuable tool to 
study suppressor T cells (213). 
Shortly, first CFSE labelling: the Cell Trace CFSE cell proliferation Kit 
(Molecular Probes, Invitrogen) was used to stain PBMCs from the same donor as the 
experimental cells according to the manufacturer’s instructions. These cells are 
referred to as responder cells. A final working concentration of 5 μM CFSE was used 
per 5 x 106 PBMCs, to obtain a CFSEhigh stained responder population, as determined 
by flow cytometry using different titrations of CFSE. CFSE expression was routinely 
evaluated after staining by flow cytometry.  
MLR: CFSE labelled PBMCs (responder cells) were cultured in 96-well round 
bottom plates at 2.5 × 104 cells/well with 5 × 104 cells/well irradiated allogenic 
PBMCs (as feeder cells) in the presence of varying amounts of experimental T cells. 
Autologous PBMCs as feeder cells for the autologous control, CD4+CD25- T cells as 
negative control and rapamycin (100 ng/ml) as positive control were plated out to 
asses their effect on proliferation. Cell cultures were stimulated with 2 μg/ml anti-
human CD3. All culture settings were performed in triplicate.  
Experimental T cells, generated with the two-step activation protocol, were 
analyzed for their suppressive function in the described MLRs after 9 days in culture 
or after 30 days in culture. The MLR was set, after 5 days cells were harvested, 
washed with PBS and the CFSE signal was analyzed by flow cytometry. Routine 
evaluation during titration experiments showed that proliferating cells lose their 
CFSEhigh staining and become CFSElow. Therefore suppression of CFSElow represents 
the suppression of proliferating responder cells compared to control (see: Figure 
2.4B), as described before (213).  
 
  




2.3 Results  
 
2.3.1 Induction of a regulatory phenotype in CD4+CD25- T cells     
CD4+CD25- T cells were activated with PMA/ionomycin and subsequently 
with anti-CD3, in the presence of IL-2 (50 U/ml). After 9 days in culture, the T cells 
from four different donors were analyzed by flow cytometry and 55% to 83% of the 
cells were shown to express the classical regulatory phenotype 
(CD4+CD25highFOXP3+, see: Figure 2.1A). Inter-donor variation was observed, but 
for every analyzed donor more than 50% of the CD4+CD25- T cells differentiated into 
(CD4+CD25highFOXP3+) Treg cells. We will refer to this inducible regulatory T cell 
population as ‘TregPMA’ cells. 
In order to demonstrate the specificity and effectiveness of our two-step 
activation procedure, CD4+CD25- T cells from three of the four donors were activated 
with PMA/ionomycin followed by IL-2 or activated with anti-CD3 followed by IL-2, 
as control groups. The cells were analyzed by flow cytometry after 9 days in culture. 
Between 0.1% and 2% of the cells in the anti-CD3/IL-2 group and between 13% and 
31% in the PMA/ionomycin/IL-2 group were shown to express the classical 
regulatory phenotype (CD4+CD25highFOXP3+) after 9 days in culture (see: Figure 
2.1B).  
  




































Figure 2.1 CD4+CD25- T cells acquire a regulatory phenotype. 
A. CD4+CD25- T cells expressing the regulatory phenotype CD4+CD25highFoxp3+, 
activated with our two-step protocol, after 9 days in culture.  
Experiments were performed in triplicate with four different donors. Mean of 
71 % (SD 13, N=4) of the CD4+CD25- T cells acquired a regulatory phenotype 
(CD4+CD25highFoxp3+). Results are presented as means +/- standard deviation (SD) 
of all four donors. 
B. CD4+CD25- T cells expressing the regulatory phenotype CD4+CD25highFoxp3+ 
after activation with our two-step protocol as compared to control groups.  
Experiments were performed in triplicate with three different donors. One 
representative experiment is shown. Depicted data are means +/- standard deviation 









2.3.2 Expression of regulatory markers by the TregPMA cells  
High CD25 expression (214) and down-regulation of CD127 (215;216) are 
established characteristics of the Treg cell phenotype in humans. Therefore expression 
of those markers on the surface of the TregPMA cells was monitored by flow 
cytometry. Furthermore, we analyzed the expression of CTLA-4, which is linked to 
Treg cell function (217;218), glucocorticoid-induced TNF receptor (GITR), linked to 
Treg cell survival (5), ICOS, linked to Treg cell function (219;220) and OX40, also 
known as CD134, which is linked to Treg cell homing and survival (5;221). 
Additionally, we analyzed the expression of IL-10, a regulatory cytokine that down-
regulates the expression of T helper cell cytokines, MHC class II antigens, co-
stimulatory molecules on macrophages and has been associated with Treg cell 
function (222).  
The TregPMA cells demonstrate down-regulation of CD127 and up-regulation 
of CD25, FOXP3, IL-10, CTLA-4, GITR, ICOS and OX40 when compared to the 
PMA/ionomycin/IL-2 control group and to non-activated T cells (see: Figure 2.2).  
To monitor the acquisition of the regulatory phenotype over time by the 
TregPMA cells in culture, the profile of expression of the established regulatory 
markers CD25, CD127, FOXP3 and IL-10 was analyzed by flow cytometry at 
different time points (see: Figure 2.3). A clear up-regulation of the Treg cell lineage 
transcription factor FOXP3 was observed over time, as well as of the markers CD25 
and IL-10. CD127 was down-regulated, further confirming the regulatory phenotype 
(215;216). For these markers the PMA/ionomycin and anti-CD3 steps seemed to act 
synergistically to achieve the expression of a regulatory profile. 
It has to be noted that the expression of CD4 at the cell surface was down-
regulated after the PMA/ionomycin activation step, but was gradually restored after 
anti-CD3 activation, as it was described before (223-225).  
The expression profiles, determined by flow cytometry of CD4+, CD25high, 
CD127-/low and FOXP3+ demonstrate that within 4 days in culture the TregPMA cells 
obtain their regulatory phenotype (see: Figure 2.3).  
Using the described TregPMA protocol we are able to generate a mean of 2.2 
x 106 TregPMA cells/ml (SD 1.0 x 106; N=3) after 9 days in culture starting from 2.5 
x 105 CD4+CD25- T cells/ml. The mean cell viability was >95% as confirmed by both 
NucleoCounter and 7-AAD staining (data not shown). 
  


























Figure 2.2 The TregPMA cells up-regulate CTLA-4, GITR, ICOS, OX40, IL-10, 
CD25, and FOXP3 and down-regulate CD127 as compared to control groups. 
TregPMA cells (black continuous line), show up-regulation of markers CTLA-4 (A), 
GITR (B),  ICOS (C), OX40 (D), IL-10 (E), CD25 (F) and FOXP3 (G) and down-
regulation of CD127 (H) after 9 days in culture as compared to not activated T cells 
(grey, filled in) and compared to PMA/ionomycin/IL-2 alone (non filled in, dotted 
line) control groups. 
Experiments were performed in triplicate and with three different donors. One 
representative experiment is shown. 
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Figure 2.3 The TregPMA cell expression profile of CD4+, CD25high, CD127low/-, 
FOXP3+ and IL-10+ the first 9 days in culture. 
TregPMA cells were analyzed at day 0, 2, 3, 4, 7 and 9 after activation. The marker 
CD127 was down-regulated, the markers CD25, FOXP3 and IL-10 were up-regulated 
and we show a synergy over time with the expression of FOXP3. 
Experiments were performed in triplicate and with three different donors. 
Results are presented as means +/- standard deviation (SD) of all three donors.  
 
2.3.3 TregPMA cells suppress the proliferation of responder cells in vitro  
Since the main functional characteristic of Treg cells is the capacity to 
suppress the proliferation of responder cells in vitro, the capacity of the TregPMA 
cells to suppress the proliferation of responder cells was analyzed by MLRs, after 9 
days in culture. A fixed number of CFSE labelled responder cells was co-cultured 
with a varying amount of TregPMA cells (responder cells to TregPMA cell ratio 1:0, 
1:0.33, 1:0.67 and 1:1.67). The cells of three different donors were analyzed. Inter-
donor variations were observed, but TregPMA cells always suppressed the 
proliferation of responder cells in co-culture with an efficacy between 25% and 43% 
(see: Figure 2.4A). The observed effect was proportional to the number of TregPMA 
cells added in the assay.  
It has to be noted that the inhibition of proliferation was most likely, not due to 
depletion of nutrients or accumulation of waste products as in the negative control the 
addition of an equal amount of CD4+CD25- T cells, instead of the TregPMA cells 
caused no inhibition of the CFSE division (see: Figure 2.4A and 2.6).  
  









































Figure 2.4 The regulatory phenotype of the TregPMA cells correlates with 
suppressive activity in vitro. 
A. TregPMA cells after 9 days in culture suppress the proliferation of responder cells 
in response to irradiated allogenic feeder cells in a CFSE based MLR. Suppression of 
CFSElow represents the suppression of proliferating responder cells as compared to 
control groups. Overall we show a mean inhibition up to 32 % (SD 9, N=3). 
CD4+CD25- T cells caused no inhibition of the CFSE division.  
Experiments were performed in triplicate. Results are presented as means +/- 
standard deviation (SD) of all three donors. 
B. Histogram of one representative flow cytometry experiment. The dotted line is the 
control group without Treg cells, showing the overall proliferation (CFSElow, 
represented in M2). The continuous line represents the experimental group; with 
1:1.67 TregPMA cells added showing less proliferation of responder cells (non-
proliferating cells in M1). 
A. 
B. 





2.3.4 Phenotype and function of TregPMA cells are stable in long term culture 
Since the sustainability of TregPMA cell phenotype and functionality over 
time is important for possible clinical applications (106), the TregPMA cells were 
kept in culture for 30 days and analyzed by flow cytometry and MLR’s.  
 
2.3.4.1 Expression of regulatory markers after long term culture 
To monitor the sustainability of the regulatory phenotype over time of the 
TregPMA cells, the profile of expression of the regulatory markers, CD127, CD25, 
FOXP3, IL-10, CTLA-4, GITR, ICOS and OX40 was analyzed by flow cytometry 
after 30 days in culture. After following our two-step protocol, the TregPMA cells of 
two different donors demonstrated a sustainable down-regulation of CD127 as well as 
up-regulation of CD25, FOXP3, IL-10, CTLA-4, GITR, ICOS and OX40 when 
compared to the PMA/ionomycin/IL-2 control group and to non-activated T cells 
(data not shown).  
 
2.3.4.2 Stable regulatory function of the TregPMA cells after 30 days in culture 
The capacity of the TregPMA cells, after 30 days in culture, to suppress the 
proliferation of responder cells was analyzed by MLRs. The TregPMA cells from two 
different donors cultured for 30 days were shown to inhibit the proliferation of 
responder cells (mean inhibition up to 40%, see: Figure 2.5).  
IL-2 contributes to FOXP3 transcription through activation of Stat5 and is thereby of 
importance both for Treg cell homeostasis and for maintaining their suppressive 
program (226). Therefore we cultured the generated TregPMA cells in the presence or 
absence of IL-2 and examined their regulatory properties. Cells of two different 
donors were analyzed by flow cytometry and it was determined that 65% and 70% of 
the TregPMA cells express FOXP3 when cultured in the presence of a low dose of IL-
2, while less than 5% of cells express FOXP3 without IL-2 supplementation (see: 
Figure 2.6). Furthermore, the TregPMA cells, cultured in the absence of exogenous 
IL-2, were not able to suppress the proliferation of responder cells in MLR’s (data not 
shown).  
 
2.4 Discussion  
This paper describes a new and simple method to generate in vitro, within 4 
days, stable and functional CD4+CD25highFOXP3+CD127low/- iTreg cells. This 
approach could be easily adapted to clinical application under Good Manufacturing 
Practices (GMP) and thereby allow the preparation of a sufficient quantity of cells to 
enable use of iTreg cells for both prevention and subsequent therapy (227). Other 
techniques to generate iTreg cells have been reported and are available (207;208). 
However, the protocol described in this paper presents a straightforward and robust 
alternative, by making use of substances which are well known, easy to obtain and 
relatively low priced.  
Our protocol consists of two steps. The first step is the activation of 
CD4+CD25- T cells with PMA/ionomycin. This combination provides a potent 
stimulation allowing us to bypass the T cell receptor activation essential for Treg cell 
development and prevent the emergence of CD4-CD8+ cells in the culture (228). PMA 
activates protein kinase C (229) while ionomycin is a Ca2+ mobilizing agent (230). 
This combination has shown to up-regulate CD25 on T lymphocytes (228) and a high 
CD25 expression is a marker of the Treg cell phenotype (214). Additionally, it was 
demonstrated that Ca2+ signalling is required for the development and function of 
Treg cells (231;232). Therefore we expected that raising the intracellular levels of 




Ca2+ in CD4+CD25- T cells using ionomycin would have a synergistic effect with 
PMA in starting a regulatory developmental program in CD4+CD25- T cells. The 
expression profiles, analyzed by flow cytometry, after activation with 
PMA/ionomycin, show a clear up-regulation of the Treg cell lineage transcription 
factor FOXP3, as well as of the markers CD25 and IL-10. Conform to the regulatory 
phenotype (215;216), CD127 was down-regulated. 
The second step in our protocol is a step of activation with anti-CD3 in the 
presence of a low dose of IL-2. This second stimulation is needed to maintain the 
regulatory developmental program, since the initial up-regulation of FOXP3 
expression, as well as the expression of CD4 on the cell surface declines in time after 
only PMA/ionomycin stimulation. Anti-CD3 was used for this purpose since it has 
been shown to maintain and expand Treg cells (233;234) and restore CD4 expression 
(225). We show here that, for the established regulatory markers, CD25high, CD127-
/low, and FOXP3+ (214-216) the PMA/ionomycin and anti-CD3 steps seem to act 
synergistically to achieve the expression of a regulatory profile within 4 days in 
culture. Furthermore, the anti-CD3 activation step in our protocol restores the CD4 
expression, which is down-regulated after the PMA/ionomycin activation step. 
IL-2 contributes to FOXP3 transcription through activation of Stat5 and is 
thereby of importance both for Treg cell homeostasis and for maintaining their 
suppressive program (226). Therefore we cultured the generated TregPMA cells in the 
presence or absence of IL-2 and examined their regulatory phenotype and function. 
We demonstrate that the expression of regulatory markers and capability of 
suppressing proliferation of responder cells in vitro are dependent on exogenous IL-2. 
Furthermore we show that in the presence of IL-2 the phenotype and function are 
stable over a long period of time.  
 
2.5 Conclusions  
Generating sufficient numbers of iTreg cells from human PBMCs and 
preserving their regulatory function for clinical application still proves to be difficult. 
In this chapter we describe a protocol which permits to induce a stable regulatory 
phenotype and function in CD4+CD25- T cells in vitro, within 4 days. We present a 
good alternative to previously established methods (207;208) by making use of 
substances which are well known, simple to obtain and relatively low priced. 
Therefore, our two-step activation protocol could be easily adapted to routine 
laboratory settings, for future clinical applications, using iTreg cells either alone or 
together with nTreg cells in the treatment of allergic, autoimmune or inflammatory 
disorders. 




Chapter 3 Murine CD4+CD25- cells activated in vitro with PMA/ionomycin and 
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T regulatory (Treg) lymphocytes are a cellular component of the immune 
system that suppresses immune responses of effector cells. As a result of their ability 
to control immune responses and to sustain systemic immune balance, they have the 
potential to prevent allergic, autoimmune and inflammatory disorders (236-245) as 
well as to be an adjuvant therapy for chronic and acute graft versus host disease (246).  
The safety profile of Treg cells has been established in phase I clinical trials 
(246;247) demonstrating that Treg cells are a suitable candidate for therapeutic 
purposes. However a major limitation to the clinical use of natural Treg (nTreg) cells 
is their low availability as they represent only a small percentage of the peripheral 
circulating CD4+ T cell population. In order to overcome this issue, several groups 
have developed different methods to expand nTreg cells in vitro when keeping their 
functionality. Generally the technologies are complex, time-consuming and the 
plasticity of nTreg cell lineage in artificial environment during ex vivo expansion can 
lead to loss of their suppressive activity (248). Furthermore their stage of 
differentiation makes their expansion in vitro a difficult process (249). 
In vitro induced T regulatory (iTreg) cells represent a good alternative to 
nTreg cells since they have been reported to have similar functionality in in vivo 
setup. Additionally iTreg cells show advantages over nTreg cells in terms of increased 
number of starting population and greater potential to proliferate (250). Therefore it is 
of importance to investigate and explore new approaches to generate iTreg cells.    
We demonstrate that phorbol myristate acetate (PMA)/ionomycin and anti-
CD3 activation of isolated CD4+CD25- T cells permits to generate in vitro, within 5 
days, induced regulatory T cells. The functionality of the generated regulatory T cells 
was demonstrated in vivo by their capacity to significantly ameliorate experimental 
colitis in the CD45RB transfer colitis mouse model. The anti-inflammatory and 
protective effect in the intestine was reflected in decreased levels of colonic 
proinflammatory cytokines IL-1β and IL-6 in the group which was treated with iTreg 
cells generated with PMA/ionomycin/anti-CD3 activation. 
 
3.2 Material and Methods 
 
3.2.1 Mice 
BALB/C and C.B.-17 SCID mice (8-10 weeks) were obtained from Harlan 
and maintained in specific pathogen-free conditions. Mouse experiments were 
approved by the local animal welfare committee (University of Amsterdam). 
 
3.2.2 Generation of regulatory T lymphocytes (Treg PMA cells) 
Splenocytes were isolated from BALB/C mice. CD4+ CD25-  T cells were 
isolated from splenocytes by means of negative selection using the mouse “CD4+ T 
Cell Isolation Kit” followed by “CD25 MicroBead Kit” (Miltenyi Biotec). Cells were 
seeded at day 0 at 1x105/well into anti-CD3e (0.5 μg/well, clone 145-2C11, 
eBioscience) coated 96-well flat bottom plates (Costar) and cultured in X-VIVO 15 
medium (Lonza) at 37°C in a 5% CO2 incubator. On day 1, cells were activated with 
PMA (10ng/ml) and ionomycin (250 ng/ml) and at day 2, 3 and 4 supplemented with 
20 U/well of IL-2 (eBioscience). On day 5, prior to use, cells were harvested and 
treated with “Dead Cell Removal Kit” (Miltenyi Biotec).  
 
3.2.3 Flow Cytometry Analysis 
Cells were analyzed using flow cytometry (FACSCalibur, BD Biosciences). 
For Treg cell staining the mouse “Regulatory T cell Staining Kit” was used which 




consisted of anti-mouse CD4 FITC (clone RM4-5), anti-mouse CD25 APC (clone 
PC61.5) and anti-mouse/rat Foxp3 PE (clone FJK16). Additional monoclonal anti-
mouse flow cytometry antibodies used in this study were as follows: anti-mouse 
CD152 (CTLA-4) APC (clone UC10-4B9), anti-mouse GARP PE (clone YGIC86), 
anti-mouse/rat CD278 (ICOS) FITC (clone C398.4A) and anti-mouse CD134 (OX-
40) APC (clone OX86). All antibodies were obtained from eBioscience. 
 
3.2.4 Induction of CD45RB Transfer Colitis Model and Treatment with 
TregPMA cells 
Chronic colitis was induced in C.B.-17 SCID mice by intraperitoneal (IP) 
injection of CD45RBhigh cells (4 x 105) isolated from normal BALB/C mice 
splenocytes (positive control group). Mice that received CD45RBhigh cells in 
combination with CD45RBlow cells were protected from disease development 
(negative control group). The treatment group received CD45RBhigh cells in 
combination with in vitro generated TregPMA cells (TregPMA cell treated group). 
The amount of TregPMA cells injected per mouse was 1.2 x 106.  
 
3.2.5 Monitoring development of colitis 
The primary read-out to assess the development of colitis was the body weight 
loss. Mice were weighed three times a week. Body weight loss was determined by 
percentage of weight loss from base line body weight.  
After sacrifice, colon was excised and longitudinally divided into 2 parts both 
of which were rolled up: one was used for preparation of paraffin embedded samples 
while the other was snap frozen in liquid nitrogen. Disease activity index (DAI) was 
calculated by combining the scores applied to weight loss (0: <1%; 1: 1-5%; 2: 5-
10%; 3: 10-15%; 4: >15%), stool consistency at sacrifice (0: normal; 1: loose 
droppings; 2: loose stools, colon filled with feces; 3: loose stool, feces only near 
caecum, 4: empty bowel) and rectal bleeding (0: negative; 2: positive; 3: gross 
bleeding) divided by three.      
 
3.2.6 Histology 
The half divided colon tissue was fixed in 4% paraformaldehyde and 
embedded in paraffin. The colon tissue was cut in 5 μm sections and stained with 
hematoxylin and eosin for histological scoring. An experienced pathologist blinded to 
experiment inspected microscopically all sections and graded them on a scale 0 to 4 
looking at: mononuclear and polymorphonuclear infiltrate, goblet cell depletion, crypt 
loss, epithelial hyperplasia, presence of ulcerations and manifestations of crypt 
abscesses.   
 
3.2.7 Cytokine analysis 
Frozen colon tissue was crushed with the use of CryoPrep™ System (Covaris) 
and resuspended in ice-cold PBS (pH 7.2) containing complete protease inhibitor 
(Roche). Homogenates were then centrifuged at 15000 x g for 5 min at 4°C and the 
supernatants were stored at -80ºC until the cytokine assay. Prior to cytokine analysis 
total concentration of the protein in supernatants was determined with the use of 
Bradford assay (Biorad). Colonic tissue and plasma levels of IL-1β, IL-6, IL-10, IL-
17 and TNF-α were analyzed using a mouse cytokine magnetic bead-based multiplex 
assay (Biorad) according to the manufacturer’s instructions. Additionally TGF-β 
levels were analyzed with Bio-Plex Pro TGF-β assay (Biorad) according to 
manufacturer’s instructions.  
 




3.2.8 Statistical analysis 
Data were analyzed statistically and graphed using Prism 5.0 (GraphPad 
Software). Changes in mice weekly body weight, body weight at sacrifice, disease 
activity index (DAI), histological score and cytokine levels are shown as mean ± 
standard deviation (SD) and analyzed by one-way ANOVA, followed by Bonferroni’s 




3.3.1 CD4+CD25- T cells acquire a regulatory T cell phenotype through 
PMA/ionomycin/anti-CD3 mediated activation 
In order to generate regulatory T cells, CD4+CD25- cells from Balb/C mice 
were activated overnight on 96-well plate coated with anti-CD3. Subsequently 
PMA/ionomycin and IL-2 were added to the cell culture. After 5 days in culture, the 
cells were analyzed for their phenotype by flow cytometry. Between 85.26% and 
91.85% of the cultured cells were shown to up-regulate and co-express the CD4 and 
CD25 markers (mean 91.4 ± 5.9%, n=3, see: Figure 3.1 A, C). 
 Additionally, we analyzed the expression of Foxp3, CTLA-4, GARP, ICOS 
and OX-40 markers which are known to be associated with a T regulatory cell 
phenotype and function (251-255). All tested markers were found to be up-regulated 
in ~30% of the CD4+CD25+ T cells after activation (a representative result is shown 
in Figure 3.1 D, Figure 3.2 A, B, C, D). 
Similarly to previously reported data with iTreg cells generated in vitro (256), 
the cellular level of Foxp3 expression in the cells activated with 
PMA/ionomycin/anti-CD3 appears to be low (see: Figure 3.1 B, D).  
We will refer to the cells treated with PMA/ionomycin/anti-CD3 activation 
(iTreg cell population) as ‘TregPMA’ cells. 
  






Figure 3.1 CD4+CD25- cells acquire regulatory phenotype- CD4+CD25highFoxp3+.  
After activation with PMA/ionomycin/anti-CD3 and 5 days in culture, the 
CD4+CD25- T cells were analyzed by flow cytometry and 85.26% to 91.85% (mean: 
91.4 ± 5.9%, n=3) of the cells were shown to co-express CD4 and CD25 marker (A) 
and mean of 36.86 ± 7.46% of the cells acquire the classical regulatory phenotype- 
CD4+CD25highFoxp3+ (B). Three independent experiments were performed (A, B). 
Representative overlays of CD25 histograms(C) and Foxp3 (D) before (in red) and 
after (in blue) PMA/ionomycin/anti-CD3 activation and 5 days in culture. One 









Figure 3.2 CD4+CD25- cells up-regulate markers associated with regulatory 
phenotype.  
TregPMA cells express the markers CTLA-4 (A), GARP (B), ICOS (C) and OX40 
(D) associated with a regulatory phenotype and function. Representative histogram 
overlays are shown. In red CD4+CD25- T cells at time 0 and in blue TregPMA cells 
after following PMA/ionomycin/anti-CD3 activation and 5 days in culture 
  




3.3.2 TregPMA cells ameliorate the disease phenotype in a colitis transfer mouse 
model 
IBD was induced in C.B-17 SCID mice by transfer of CD45RBhigh cell 
population from BALB/C mice (positive control group) and was prevented by co-
transfer of CD45RBlow cell population (negative control group) (257-260). 
The read-out parameters of the development and progression of the colitis in 
the transfer mouse model are body weight loss and inflammation of the intestinal 
tissue. 
The positive control group developed colitis and presented a relative decrease 
of initial body weight 86.88 ± 5.06% (n=9) at sacrifice which was significantly lower 
than the negative control that reached 110 ± 3.29% (n=10) of the initial body weight. 
The TregPMA cell treatment (injection of TregPMA cells together with CD45RBhigh 
cells) reduced significantly the body weight loss to 99.18 ± 7.17% (n=10) as 
compared to the positive control group (Figure 3.3 A, B).    
The Disease Activity Index (DAI), which is an indicator of colonic 
inflammation, reflecting weight loss, stool consistency and presence of rectal bleeding 
was determined at sacrifice. The DAI was significantly lower in mice treated with 
TregPMA cells (1.18 ± 0.55) when compared to the positive control group (2.04 ± 
0.35), confirming the amelioration of the disease phenotype (Figure 3.3 C). 
Intestinal inflammation was further determined by histopathological analysis 
of colon tissue post mortem which includes evaluation of mononuclear and 
polymorphonuclear cell infiltrate, goblet cell depletion, loss of crypts, epithelial 
hyperplasia and manifestations of ulcerations and abscesses (257-260).  
A significant reduction of inflammation was observed in the colon tissue of 
the TregPMA cell treated mice when compared to the positive control group (Figure 
3.3 D). The spread of intestinal inflammation was less extensive and no ulcerations 
were observed in the TregPMA cell group (Figure 4.B) which was similar to the 
negative control group (Figure 3.4 A) while in the diseased control group they were 
commonly present (Figure 3.4 C). 
 
 







Figure 3.3 Amelioration of the disease phenotype in TregPMA cell treated mice. 
Mice that were injected with CD45RBhigh cells only developed colitis (positive control 
group, n=9) while the mice that were injected with CD45RBhigh and CD45RBlow cells 
together remained healthy (negative control group, n=10). The experimental group 
was injected with CD45RBhigh and TregPMA cells (n=10). Disease progression was 
assessed by changes in weekly body weight (A) as well as macroscopic and 
microscopic scores at day of sacrifice which comprises of Disease Activity Index (C) 
and Histological Score (D). 
TregPMA cell treated mice showed to have reduced weight loss over time (A) 
and at the time of sacrifice (B) when compared to positive control. The change of 
weight is expressed as the mean percentage of initial weight per group ± SD. Disease 
Activity Index (DAI), calculated from combining scores applied to weight loss, stool 
consistency at sacrifice and rectal bleeding divided by three, shows a significant 
difference between groups (C) as well as Histological Score of the H&E stained colon 
tissue sections (D). The data were analyzed using one-way ANOVA, followed by 
Bonferroni’s Multiple Comparison Test. *P<0.05, **P<0.01, ***P<0.001, 
****P<0.0001   
 





Figure 3.4 Histopathology of mouse colon.  
Representative whole-colon photographs of H&E stained tissue sections of negative 
control mouse (A), TregPMA cell treated mouse (B) and positive control mouse with 
ulceration manifestation (C).  
 
3.3.3 Proinflammatory cytokine production in colon and in plasma of TregPMA 
cell treated mice is reduced 
  We next examined the influence of TregPMA cell treatment on the production 
of pro-inflammatory cytokines IL-6, IL-1β and TNF-α that have been previously 
described to be increased in CD45RB transfer colitis mouse model (261;262). The 
level of IL-10 and TGF-β that have been shown to have a regulatory effect in 
experimental colitis were also analyzed (263;264). Additionally the level of IL-17 
cytokine that have been described to have both pro- and anti-inflammatory effect in 
IBD was measured (263;265-268).   
The level of IL-6 was found to be decreased in TregPMA cell treated group in 
both colon homogenates and plasma at the day of sacrifice when compared to the 
positive control group (Figure 3.5 A, D). IL-1 β level was also found to be reduced 
after TregPMA cell treatment in colon homogenates but this decrease was not 
reflected in plasma (Figure 3.5 B, E).  
Elevated levels of IL-17 were found in colon tissue homogenates of TregPMA 
cell treated mice as well as in positive control group. However, the TregPMA cell 
treated group had higher level of colonic IL-17 than the positive control (Figure 3.5 
C). No significant difference between groups was observed in the levels of IL-17 
expression in plasma (Figure 3.5 F). 
 TNF-α, IL-10 and TGF-β levels in both colon homogenates and plasma 
showed no significant differences between groups (data not shown).      





Figure 3.5 Cytokine levels in mouse colon homogenates and plasma.   
Colonic tissue homogenates and plasma levels of IL-1ß (A, D), IL-6 (B, E) and IL-17 
(C, F) of negative control group (n=10), TregPMA cell treated group (n=10) and 
positive control group (n=9) were analyzed using a mouse cytokine magnetic bead-
based multiplex assay. TregPMA cell treatment has shown to suppress increased 
levels of colonic IL-1ß (A), IL-6 (B) and plasma IL-6 (E) in CD4+CD45RBhigh CD25- 
cell transferred colitic mice. The data were analyzed using one-way ANOVA, 
followed by Bonferroni’s Multiple Comparison Test. *P<0.05, **P<0.01, 
***P<0.001, ****P<0.0001   
 
  





In this article we describe the generation of iTreg cells (TregPMA cells) in 
vitro from CD4+CD25- cells by PMA/ionomycin/anti-CD3 activation based method. 
Mechanistically, PMA/ionomycin provides a potent stimulation allowing us to 
bypass the T cell receptor activation essential for Treg cell development and it 
prevents the emergence of CD4-CD8+ cells in the culture (269). PMA activates 
protein kinase C (270) while ionomycin is a Ca2+ mobilizing agent (271). This 
combination has been shown to up-regulate CD25 on T lymphocytes (269) and a high 
CD25 expression is a marker of the Treg cell phenotype (272). Additionally, it was 
demonstrated that Ca2+ signaling is required for the development and function of Treg 
cells (273;274). Therefore we expected that raising the intracellular levels of Ca2+ in 
naive T cells using ionomycin would have a synergistic effect with PMA in starting a 
regulatory developmental program in CD4+CD25- cells. Additionally a low dose of 
IL-2 was used in cell culture since IL-2 is important for Treg cell homeostasis and 
maintaining their suppressive survival program (275) while anti-CD3 which is also 
present in the cell culture has been shown to maintain and expand Treg cells (276).  
The TregPMA cells up-regulate CD25, and ~30% of the CD4+CD25+ T cells 
up-regulate CTLA-4, GARP, ICOS, OX-40 and Foxp3 which are important markers 
associated with regulatory cell phenotype and function (251-255;277;278). 
Interestingly, the level of Foxp3 expression in TregPMA cells is quite low. Although 
Foxp3 expression is considered to be a main characteristic of Treg cells, Treg cells are 
recognized to be a heterogeneous cell population. Especially, it has been reported that 
CD4+CD25+ Foxp3- cell population also can present regulatory function in vitro and 
in vivo (256). 
TregPMA cells have been shown to be functional in vivo by mediating the 
amelioration of the disease phenotype in a CD45RB transfer colitis mouse model. The 
disease amelioration was accompanied by a decrease of the pro-inflammatory IL-1 β 
levels in the colon tissue which reflect the severity of experimental colitis (261). Such 
a decrease in IL-1 β was previously reported by Hirano and Kudo after treatment of 
CD45RB transfer colitis mouse model with both dexamethasone and anti-tumor 
necrosis factor-α (anti-TNF-α).  
IL-1 β stimulates the production of the pro-inflammatory cytokine IL-6 (279) 
which has been described to be up-regulated in mouse model of IBD (280) and in 
human ulcerative colitis or Crohn’s disease patients (281). Simultaneously with the 
decrease of IL-1β in our study, IL-6 levels were found to be reduced in both colonic 
homogenates and plasma samples after treatment with TregPMA cells.  
 The concentration of IL-17 was found to be more elevated in colon 
homogenates of TregPMA cell treated mice than in the positive control group. 
Although the role of this cytokine in the initiation or pathogenesis of IBD is 
controversial, a protective function of IL-17 in the gut of CD45RB transfer colitis 
model has been previously noted (263;266;282). Several groups have reported that 
both IL-17-/- CD45RBhigh and IL-17R-/- CD45RBhigh cells induce a more aggressive 
disease phenotype than wild type CD45RBhigh cells (263;282) . Accordingly, our 
results show that an increased IL-17 level also correlated with less severe intestinal 
inflammation and lack of ulcerations.   
 IL-10 and TGF- β cytokine level in both mouse plasma and colon 
homogenates show no significant differences between experimental groups at the time 
of experiment termination (week 7). However, it does not exclude the possible 
influence of those cytokines on prevention of the colitis induction at earlier time 
point. 




The cells that have been found mostly responsible for pathogenesis of 
CD45RB transfer model of IBD are Th1 cells. Recently it has been shown that IL-17 
blocks the Th1 cell development in vivo via IL-17R on naive CD4+ T cells (263;282). 
In the TregPMA cell treated group we also observe elevated level of IL-17 which 
correlates with disease amelioration. IL-17 can be produced by many types of cells 
among which are also T regulatory cells (283). Therefore we are hypothesizing that in 
vivo disease amelioration by TregPMA cells is IL-17 mediated but further 
investigation is needed to determine the physiological relevance of TregPMA cells 
and their exact molecular mechanism of action. 
 
3.5 Conclusions 
Induced regulatory T cells are promising tools for therapeutic applications in 
IBD (284) as well as in other autoimmune disorders and are of great scientific interest 
and many techniques to generate inducible Treg cells from naive T cells have been 
developed and described (243;285-288). Different activation methods to generate 
iTreg cells result in iTreg cells that are heterogeneous in phenotype. The in vitro 
PMA/ionomycin/anti-CD3 activation of CD4+CD25- T cells has proven to generate 
functional iTreg cells (TregPMA cells) but the in vivo physiological relevance of 
TregPMA cell signalling needs to be further investigated. 
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Inflammatory bowel diseases (IBD) are comprised of two major disorders: 
Crohn's disease (CD) and ulcerative colitis (UC). These disorders have distinct and 
overlapping characteristics (289). Both are chronic inflammatory diseases most 
commonly affecting young adults. The pathogenesis remains incompletely 
understood, but it is now widely accepted that IBD results from an inappropriate 
response of a defective mucosal immune system to the intestinal flora and other 
luminal antigens (2;290). No curative treatment options are available for IBD. 
Conventional therapeutic options cannot prevent complications in IBD and 
although novel treatment strategies, including TNF-neutralizing antibodies, have 
greatly increased the therapeutic armamentarium, many patients still undergo surgery 
(27). For the future, development of treatment which is patient tailored and prevents 
initiation of inflammation is essential. 
There is potential for the application of gene therapy in diseases related to the 
gastrointestinal tract (reviewed extensively by Londei et al. (291), Prieto et al. (292) 
and Wirtz et al. (293)) and adeno-associated viruses (referred to as AAV) are leading 
candidates for gene therapy (31;32) as those vectors have been described to be able to 
target the gut (48;49). During and colleagues showed that oral administration of AAV 
yields stable transduction of the gut epithelium (49). Polyak and colleagues 
demonstrated AAV vector-mediated gene delivery to intestinal epithelial cells in vitro 
and in vivo using serotypes 1, 2 and 5 (48) and long term transgene expression post 
AAV treatment suggests that transduction of crypt progenitor cells is possible (48;49). 
A potential barrier to application of AAV vectors in IBD patients is pre-
existing immunity as a consequence of exposure to wild type AAV (170-172). 
Neutralizing antibodies (nAbs) made in response to exposure to either wild type AAV 
or AAV-based vectors have been associated with a partial to complete block of 
transduction. For example, an inverse correlation between the pre-existing capsid 
neutralization titer and AAV based HIV-vaccine efficacy has been reported (173). In 
experiments where the AAV is being re-administered, the level of nAbs seems to be 
proportional to the virus dose used for the first injection and transgene expression 
following re-administration is dependent on pre-existing nAb titer (174). Therefore it 
is important to know pre-existing nAb titer in future patient populations.  
No data are available for the prevalence of neutralizing antibodies to the 
different AAV serotypes in IBD patients. A lower prevalence of nAbs against certain 
serotypes may be expected, as compared to a healthy population, given the immune 
system suppressing drugs taken by these patients. Furthermore, it is known that IBD 
patients mount less of a humoral immune response after tetanus toxin immunization, 
suggesting the presence of humoral immune defects in IBD (175).  
In order to establish a foundation for the setup of a gene therapy approach as a 
novel treatment strategy in IBD, we designed this study to characterize the pre-
existing humoral responses to the AAV capsid.  
  
  




4.2 Material and methods  
 
4.2.1 Cell culture 
Human embryonic kidney 293 (HEK293) cells were maintained in Dulbecco’s 
modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum 
(FBS). 
 
4.2.2 Samples  
Healthy donors, whole blood samples of healthy donors from the Dutch 
population (N=100, see: Table 4.1) were obtained from the blood bank (Sanquin, 
Amsterdam the Netherlands), after informed consent and serum was stored in -80ºC 
until analysis. 
IBD patients, whole blood samples of patients diagnosed with either CD (N= 
101) or UC (N= 99) were obtained after informed consent and serum was stored in -
80ºC until analysis (N=200, see: Table 4.1). Characteristics of the patient population 
are depicted in Table 4.2. 
 
4.2.3 AAV vector production and characterization 
AAV vectors were produced (technology adapted from Negrete and Kotin 
(294)) containing green fluorescent protein (GFP), under the control of the 
cytomegalovirus (CMV) promoter as transgene. AAV was purified with an anion 
column using the ÄKTAexplorer system (GE-Healthcare). After purification, 
presence of AAV capsid proteins (VP1, VP2 and VP3) was determined by 
polyacrylamide gel electrophoresis and concentration of vector genomes (gc/ml) 
determined by qPCR. The biological activity was established by treating HEK293 
cells with dilutions of rAAV and measuring the GFP positive cells, using flow 
cytometry (FACScalibur, Becton Dickinson) in channel FL1 at a wavelength of 530 
nm. 
 
4.2.4 Virus neutralizing assay 
HEK293 cells were seeded in a 96 wells plate (Corning) coated with 0.25% 
poly L-lysine at a density of 1 x105 cells/well in 100 μl DMEM with 10% FBS and 
antibiotics (Penicillin/Streptomycin Solution). Cells were incubated overnight at 
37°C. Medium was then removed and the following mix was added: rAAV (-1, -2, -3, 
-4, -5, -6 or -8) -CMV-GFP, incubated with heat-inactivated serum sample and with 
wild type-adenovirus (Viraquest) at a dilution of 1:4000 in a total volume of 100 μl of 
DMEM with antibiotics. The mix was kept for 1 hour at 4°C before being added. 
Medium of the HEK293 cells was removed by aspiration and the mix added for 20 hr 
at 37°C. The final dilutions of the test serum were 1:100, 1:200, 1:400, 1:800, 1:1600, 
1:3200, 1:6400, and 1:12800. As a positive control cells without serum were 
analyzed. The cells were washed with PBS and collected after trypsinisation. GFP 
expression of the cells was analyzed by fluorescence-activated cell sorting 
(FACScalibur, Becton Dickinson) in channel FL1 at a wavelength of 530 nm. The 
analysis was performed with the Cellquest software. The percentage of inhibition was 
calculated related to GFP expression measured in rAAV HEK293 infected cells (no 
inhibition, 100% expression). Dilutions of animal serum less than 1:100 exhibit 
nonspecific inhibition of vector transduction, so we did not examine the effects of 
human serum diluted less than 1:100. 
The assay was performed in a research setting with no particular specifications 
regarding QA/QC. The assay was performed according to written previously 




established protocols and quality controls were included in each assay run to 
guarantee optimal quality of the data generated. 
Serum samples were considered to have neutralizing activity if the 1:100 
serum dilutions inhibited vector transduction by at least 50%, as described before 
(170-172). The serum was further categorized as having low, medium, or high titer if 
a 50% or greater reduction in vector transduction was achieved with the ≤1:800, 
1:800-1:6400, or ≥1:12800 dilutions, respectively. 
 
4.2.5 Statistical analysis 
Results are presented as means (+/- standard deviation (SD), when 
appropriate). Statistical analyses were performed using Prism 5.0 (GraphPad) or the 
SPSS software package. The Fisher's exact test was used to analyze differences in 
prevalence of nAbs between the IBD patients and healthy controls and potential 
associations between selected risk factors and the presence of nAbs between different 
subgroups. The Holm–Bonferroni method was used to correct for multiple 
comparisons.  
A logistic regression model was used to analyze the influence of age at the 
moment of blood donation on the prevalence of nAbs in the serum. When analyzing 
the influence of age at the moment of diagnosis of IBD on the prevalence of nAbs, a 
correction was made for age at the moment of blood donation (Binary logistics, in the 
SPSS software package). The Bonferroni method was used to correct for multiple 
comparisons. For all the analysis performed a p-value less than 0.05 was considered 
statistically significant.  
 
4.3. Results  
 
4.3.1 Prevalence of neutralizing antibody to AAV  
Serum samples were obtained from 300 donors (100 healthy control, 101 CD 
and 99 UC patients) and the validated virus neutralization assay was performed as 
described in the material and methods section. Samples were heat-inactivated to 
prevent influences from components other than immunoglobulins on the virus 
neutralization assay (172). 
The percentage of serum samples showing neutralization is depicted in Figure 
4.1, for both IBD patients and for the healthy controls. After correction for multiple 
comparisons, a significant difference has been detected in nAbs for the AAV types 1, 
5, 6 and 8, between the healthy donors and the patient population. Against AAV types 
1, 5 and 8 IBD patients show a lower prevalence of nAbs and against AAV6 a higher 
prevalence (see: Figure 4.1). In the healthy donors the prevalence of antibodies to 
AAV8 (94%) was the highest and to AAV4 (31%) the lowest. For the IBD patients 
the prevalence of antibodies to AAV6 (85%) was the highest and to AAV4 (44%) the 
lowest.  







Figure 4.1 Percentage serum samples showing neutralization of transduction by 
the different AAV serotypes for healthy donors from the Dutch population 
(N=100) compared to IBD patients (N=200). 
Depicted above the figures are the P values, corrected for multiple comparisons, for 
the statistically significant differences. 
AAV; adeno associated virus, IBD= inflammatory bowel diseases.  
 
 
4.3.2 Titer of neutralizing antibody in the positive serum samples 
Since it has been shown that transgene expression is negatively affected by 
pre-existing nAb titer (174), we measured serum neutralizing activity to all the AAV 
serotypes studied. When a serum sample was positive for nAbs to an AAV serotype 
we established the titer of nAbs to that serotype. Sub-groups were determined for 
having a low, medium, or high titer as described in the material and methods section. 
We found in both the healthy (see: Figure 4.2) and in the IBD patient 
population (see: Figure 4.3) a low titer against AAV4 (100% and 99%, respectively) 
and AAV5 (99% and 98%, respectively). Therefore we show, in accord with our 
classification, a favorable pre-existing humoral immune response to these serotypes.  
 
To conclude, we demonstrate the prevalence of nAbs against AAV1, -2, -3, -4, 
-5, -6 and -8 for both the IBD population and for a large group of healthy controls. In 
both groups we demonstrate that AAV4 and AAV5 show potential as gene therapy 
vectors based on the low titer of nAbs in the positive serum samples. A summary of 
these results is presented in Table 4.3. 
 





Figure 4.2 Titer of nAbs in the positive serum samples from healthy donors in 
the Dutch population. 
Neutralization titer (low, medium and high) for the positive serum samples per AAV 
serotype. Samples positive for AAV4 (100% have a low titer) and AAV5 (99%) show 
predominantly a low titer of nAbs.  




Figure 4.3 Titer of nAbs in the positive serum samples from IBD patients. 
Neutralization titer (low, medium and high) for the positive serum samples per AAV 
serotype. Samples positive for AAV4 (99% have a low titer) and AAV5 (98%) show 
predominantly a low titer of nAbs.  
NAbs; neutralizing antibodies, AAV; adeno associated virus, IBD; inflammatory 
bowel diseases. 
 
4.3.3 Subgroup analysis 
Our patient population was divided according to the disease characteristics 
depicted in Table 4.2 since these characteristics are linked to disease severity, 




duration, amount of immune suppressive medication and possibly to immuno-
pathology.  
Furthermore a possible correlation with gender (see: Table 4.1) has been 
analyzed. 
 
4.3.3.1 Mean age at blood donation 
It has been suggested that a correlation exists between ages and nAbs to 
different AAV serotypes (172), because AAV infections seem to occur at all ages.  
For all the serotypes studied in both the IBD patients and the healthy donors 
we show that the prevalence of nAbs indeed increases with age, confirming previous 
reports (172). For the IBD population these results were statistically relevant, after 
correction for multiple comparisons, for AAV1 (p = 0.02), AAV2 (p = 0.001), AAV3 
(p = 0.001), AAV4 (p = 0.04) and AAV8 (p = 0.02). For the healthy population these 
results were statistically relevant, after correction for multiple comparisons, for AAV1 
(p = 0.03), AAV2 (p = 0.01), AAV3 (p = 0.001), AAV4 (p = 0.001) and AAV6 (p = 
0.001). 
 
4.3.3.2 Mean age at diagnosis  
Polito and colleagues suggested the existence of subgroups within the diverse 
entity of IBD, according to differences in the age at diagnosis (295). This assumption 
is based on the remarkable bimodal age distribution shown in IBD (290;296;297). 
Therefore we analyzed our data accordingly, dividing the IBD patient population into 
three age groups according to their age at the time of diagnosis (20 and younger, 20-
40 and 40 years and older), as described previously (295).   
The younger the patient was at the time of diagnosis, the lower the prevalence 
of nAbs in the serum for all the studied serotypes (see: Figure 4.4). Therefore we 
show a correlation, as suggested previously by Polito and colleagues, namely there 
being subgroups within the diverse entity of IBD, according to differences in the age 
at the moment of diagnosis (295). 
 
4.3.3.3 Crohn’s disease and Ulcerative colitis 
For all the serotypes analyzed, the prevalence of nAb s was lower in the CD 
than in the UC patients (data not shown). The results obtained show a trend within the 
IBD population of a lower prevalence in infectious serology as observed in CD as 
compared to UC patients, as has been suggested before (298-300). 
 
4.3.3.4 Extra intestinal manifestations 
For all the studied serotypes the prevalence of nAbs was higher if the patient 
had extra intestinal manifestations of disease. After correction for multiple 
comparisons a significant difference was found for AAV3 (see: Figure 4.5). 
For the remaining disease characteristics as depicted in Table 4.2 as well as 
for gender (see: Table 4.1), we did not find any relationship with the prevalence of 
nAbs in the serum for all the studied serotypes.  
 
 





Figure 4.4 IBD patients divided according to their age at the time of diagnosis. 
Age groups were made ≤20 (N=48), 20-40 (N=129) and ≥40 (N=23) years at the time 
of diagnosis. A trend is observed; the younger the patient was at the time of diagnosis 
the lower the prevalence of nAbs to all the serotypes studied. 





Figure 4.5 IBD patients divided according the presence of extra intestinal 
manifestations. 
Yes (N=45) and No (N=155) extra intestinal manifestations. For every serotype the 
prevalence is higher if the patient has extra intestinal manifestations of disease.  
Depicted above the figures are the P values, corrected for multiple comparisons, for 
the statistically significant differences. 
NAbs; neutralizing antibodies, AAV; adeno associated virus, IBD; inflammatory 
bowel diseases. 
  




 Healthy donors 
IBD patients 
Overall CD UC 
N 100 200 101 99 
Mean age, yr (SD) 49 (13) 43 (14) 43 (15) 42 (13) 
Min, yr 20 16 16 19 
Max, yr 69 84 84 81 
Sex Females 44 116 61 55 
 Males 56 84 40 44 
 
Table 4.1 Demographics of the study population. 
Yr; years, SD; standard deviation, Min; minimum, Max; maximum, IBD; 





Overall CD UC 
N 200 101 99 
Mean age, yr (SD) 43 (14) 43 (15) 42 (13) 
Mean age at diagnosis, yr (SD) 28 (10) 26 (10) 30 (11) 
Min age at diagnosis, yr 8 8 8 
Max age at diagnosis, yr 66 64 66 
Number of patients with perianal disease 45 41 4 
Number of patients needing surgical resection 
related to their IBD 82 65 17 
Number of patients with extra intestinal 
manifestations 45 27 18 
Number of patients with a positive family history 
for IBD 19 13 6 
Number of patients that developed cancer 2 2 0 
 
Table 4.2 Characteristics of the patient population. 
Yr; years, SD; standard deviation, Min; minimum, Max; maximum, IBD; 
inflammatory bowel diseases, CD; Crohn’s disease, UC; ulcerative colitis 
  




Prevalence of neutralizing antibodies to the different AAV serotypes: overview 
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Serotypes for which a statistical 
relevant difference has been 
established between the two groups 
Characteristics 
nAbs in the serum samples (%) 
Healthy controls IBD patients 
AAV1 79 63 
AAV5 77 53 
AAV6 67 85 
AAV8 94 70 
 
 
Table 4.3 Summary table paragraph 3.1 and 3.2. 
NAbs; neutralizing antibodies, AAV; adeno associated virus, IBD; inflammatory 
bowel diseases 




4.4 Discussion  
In this paper we characterize for the first time the pre-existing humoral 
responses to the AAV capsid in IBD patients (both CD and UC). We demonstrate 
significant differences in neutralizing antibodies between the general healthy 
population and an IBD patient population. Furthermore we show a relationship 
between disease phenotype in IBD patients and the humoral immune response to 
AAV. 
Given the considerable morbidity and the relative young age of onset in IBD, 
combined with the lack of curative treatment options, there is a need to explore new 
ways in restoring long term immune tolerance for this particular group of diseases. 
Gene therapy, which has been successful for the treatment of both acquired and 
genetic diseases in recent years, has the potential to achieve this goal. AAV is 
frequently used for gene therapy in a clinical setting (31;32;301) and has proven to be 
a safe and reliable vector for multiple applications. For the treatment of IBD it could 
be the vector of choice as it has been shown to target the gut (48;49). Additionally, 
there have been no adverse events in clinical trials directly attributed to AAV (302) 
(the prospects for the use of the AAV as a vector for human gene therapy were 
extensively reviewed by Kotin (135)). 
An important factor that has to be considered, before further exploring a 
possible application using AAV in the gut, is the presence of neutralizing antibodies 
to the different AAV serotypes. Knowledge about circulating antibodies can both 
direct the choice of the serotype and help design strategies to evade possible 
undesirable side-effects of AAV based technologies. Therefore it is important to 
define pre-existing humoral immune status of the population before exploring this 
treatment option in the future for IBD patients. 
We studied the prevalence of nAbs against AAV1, -2, -3, -4, -5, -6 and -8 for 
both an IBD population and for a large group of healthy controls. A significant 
difference was detected in nAbs for the AAV types 1, 5, 6 and 8 as compared to the 
healthy controls. Against AAV types 1, 5 and 8 IBD patients show a lower prevalence 
of nAbs, against AAV6 a higher prevalence. It has been shown that IBD patients are 
less likely to mount a humoral immune response after vaccination (175) and therefore 
our observation of a higher prevalence of nAbs against AAV6 in the IBD patient 
population as compared to the healthy population is remarkable. This subject needs to 
be further explored, since apart from its importance for a future gene therapy 
application it could give additional inside in the immune-pathogenesis of IBD.  
Data concerning nAbs against AAV3 and -4 have not been previously 
publicized. We show that against AAV4, in both the healthy and the IBD patient 
population the overall nAbs prevalence is relatively low (<50%). Furthermore in the 
positive samples (100% of the healthy donors and 99% of the IBD patient population 
have a low titer) a favorable pre-existing humoral immune status is demonstrated. 
Equally, AAV5 (99% and 98% of positive samples, respectively) shows great 
promise, as has been described before (170;172). Therefore, these vectors could be 
considered in a gene therapy approach for IBD patients. 
For every serotype the prevalence is lower if the patient was diagnosed with 
CD as compared to UC. Furthermore, we observed a difference of the prevalence of 
nAbs in the serum in the IBD patient population according to the age at diagnosis. For 
every serotype the prevalence is lower if the patient was younger when the disease 
was diagnosed. For every serotype the prevalence is higher if the patient has extra 
intestinal manifestations of disease. These data suggest an influence of disease 
phenotype on the immune status of the IBD patient and emphasize the need for a 
tailored approach in the setup of a gene therapy application. A possible explanation 




for the observed differences could be that they represent aspects of different disease 
subgroups within the diverse entity that is IBD, as was for example suggested with 
respect to age at diagnosis (295). Our data support this concept of heterogeneity in 
IBD, but this subject needs to be further explored. 
The preservation of intestinal homeostasis is a central part of the future 
treatment goals in both Crohn’s disease and ulcerative colitis (as stated in a recent 
review by Sandborn (303)) Given the diverse nature of the inflammatory bowel 
diseases, current treatment options are far too non-specific to achieve this goal for 
every sub-group within the IBD patient population. For example Glocker and 
colleagues showed mutations in genes encoding the interleukin-10 (IL-10) receptor 
subunit proteins in patients with early-onset enterocolitis, involving hyper 
inflammatory immune responses in the intestine (304). Impairment of IL-10 
associated regulatory pathways appears to be critical in certain sub-groups in both 
forms of IBD, as deduced from functional and genetic studies (reviewed extensively 
by Kaser and colleagues (4)). Gene therapy allows for a strategy especially designed 
for a particular sub-group of patients, enabling, for example regional distribution of 
agents inhibiting chemokine synthesis (305;306), or local delivery of regulatory 
cytokines such as IL-10, which would circumvent current problems with systemic 
delivery (158;159).  
Our data can be used for future AAV based gene therapy as a novel treatment 
approach for IBD. The differences demonstrated here between the IBD patient 
population and the healthy controls and our data concerning the presence of nAbs and 
certain disease characteristics offer insight into the IBD pathogenesis. Furthermore, 
we present new information about neutralizing antibodies in the general, healthy 
population. In both groups we show that against AAV4 and AAV5, there is a 
favorable pre-existing humoral immune status, based on the low titers of nAbs found 
in the serum of the positive samples. These vectors could therefore be considered in a 
gene therapy approach. 
Overall, the data we present in this article characterize the pre-existing 
humoral responses to the AAV capsid in IBD patients (both CD and UC) and a large 
group of healthy controls. It allows for the development of new strategies to evade 
AAV acquired immune responses and has important implications for the setup of an 
AAV based gene therapy approach in IBD. 
  




Chapter 5 Adeno-associated virus mediated delivery of Tregitope 167 
ameliorates experimental colitis  
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Tregitopes are a set of putative regulatory T cell epitopes present in the 
immunoglobulin G molecule, which have been identified by using computational 
epitope mapping (211;307). Tregitope sequence 167 (Tregitope 167) and an 
additional sequence (Tregitope 289) were synthesized and shown to bind to multiple 
Major Histocompatibility Complex (MHC) class II molecules and to suppress 
immune response when co-administered with an antigen. Tregitopes 167 and 289 
were also shown to expand natural occurring regulatory T (nTreg) cells and to induce 
a regulatory phenotype and function in peripheral T (iTreg) cells (211;307). 
Harnessing the potential of Treg cells activated or induced by Tregitopes to regulate 
pathological immune responses in IBD may reduce the requirement for systemic 
immunosuppressive therapies. However, the use of immunomodulatory peptides in 
clinical applications for IBD so far have shown that the in vivo delivery of these 
peptides for therapeutic purposes is hindered by difficulties in obtaining sufficient and 
stable peptide concentrations (157-159). Therefore, novel means for stable delivery of 
regulatory peptides have to be explored. Adeno-associated viruses (AAV) present a 
good safety profile and have been shown to be effective as gene delivery vectors in 
the clinic for the treatment of a broad range of diseases (88;90;161). Therefore, AAV-
mediated delivery represents an attractive approach to deliver the immuno-
modulatory Tregitope peptides. 
In the present study, the potential of AAV-mediated gene therapy for the 
therapeutic delivery of Tregitope 167 was explored. Systemic AAV-mediated 
administration of Tregitope 167 was shown to ameliorate the clinical and histo-
pathological severity of Trinitrobenzene Sulfonate (TNBS) induced inflammatory 
colitis in mice. Hence, AAV-mediated delivery of regulatory T-cell epitopes appears 
to be a promising novel therapeutic approach for the treatment of IBD and could 
represent an alternative or adjunct to the use of immunosuppressive drugs. 
 
5.2 Material and Methods 
 
5.2.1 AAV vector production and characterization 
Mouse Tregitope cDNA was synthesized (Integrated DNA Technologies, IDT, 
Inc) according to the published corresponding sequence (211;307) and cloned into the 
plasmid pPSC10 (294) under the control of the cytomegalovirus (CMV) promoter. 
The Woodchuck hepatitis virus post-transcriptional enhancer (WPRE) was 
incorporated behind the Tregitope 167 cDNA to further optimize gene expression 
(308). The AAV vector, AAV5 (CMV-Tregitope 167) was produced according to a 
technology adapted from A. Negrete and R.M. Kotin (294). The AAV vector was 
purified with an anion column, using the ÄKTA explorer system (GE-Healthcare). 
After purification, the concentration of AAV vector genomes copies (gc/ml) was 
determined at 9x1013gc/ml by Taqman qPCR amplification. The biological 
infectivity of AAV5 (CMV-Tregitope 167) was demonstrated in vitro by PCR 
amplification of the “CMV-Tregitope 167” DNA fragment (product size 402bp) on 
DNA isolated from HEK293T, transduced with AAV5 (CMV-Tregitope 167). 
Primers designed and synthesized for Tregitope 167 and the CMV promoter were 
used. 
 
5.2.2 Induction of colitis and study design 
Balb/c mice (males, age 6-8 weeks) were obtained from Harlan Laboratories, 
The Netherlands. The experimental protocol was approved of by the ethical 
committee for animal welfare of the AMC (Academic Medical Center, Amsterdam, 




The Netherlands). Colitis was induced in mice by administration of TNBS 
(Trinitrobenzene sulfonate, TNBS, Sigma-Aldrich), as described previously (309). 
The general procedure is summarized in Figure 5.1. 
Mice were injected intravenously with either PBS or AAV5 (CMV-Tregitope) 
10 days before acute colitis was initiated by intra-rectal administration of 1.5mg 
TNBS in 40% ethanol. Consecutively, a second TNBS treatment (0.75mg in 20% 
ethanol) was done 8 days after the first TNBS treatment as described before (309). 
Mice not treated with TNBS (healthy control group) and mice treated with TNBS 
only (diseased control group) were used as references to monitor colitis development. 
A concomitant sham AAV control vector was not used in this study as this control has 
been shown to be equivalent to saline control (77;310). Even though AAV-mediated 
gene transfer leads to the development of neutralizing antibodies against the vector 
capsid (311), preventing vector re-administration, no inflammatory responses against 
the AAV capsid were documented in in vivo gene transfer mice models using AAV 
vectors (77;96).   
 
5.2.3 Assessment of Inflammation 
The body weights of the mice were recorded daily, and wasting disease 
progression was expressed by the percentage of weight loss as compared to body 
weight at the day of initiation of TNBS treatment (day 10, Figure 5.1). Animals were 
withdrawn from the study when their weight loss was >25% of their original body 
weight. At the time of sacrifice, colons were collected and presence of loose stool and 
visible fecal blood was assessed. 
At the time of sacrifice, a composite score (disease activity index, DAI) was 
established as described previously (309). Body weight loss was scored on a scale of 
0–4 (0, <1%; 1, 1%-5%; 2, 5%-10%; 3, 10%-15%; 4, >15%). Loose stool was scored 
on a scale of 0–4 (0, normal; 1, loose droppings; 2, loose stools, colon filled with 
feces; 3, loose stool, feces only near cecum; 4, empty bowel). Visible fecal blood was 
scored on a scale of 0–4 (0, negative; 2, positive; 4, gross bleeding). The DAI consists 
of a combination of body weight loss, loose stool and visible fecal blood scores 
divided by 3 as described previously (309). 
Colon tissue weights were recorded and used as an indicator of disease-related 
intestinal wall thickening. Increased colon weight has been shown to correlate with 
increased colon inflammation (309). Colons were first divided longitudinally into two 
parts: one part was immediately frozen in liquid nitrogen for protein extraction and 
cytokine determination, while the second part was stored in formalin and embedded in 
paraffin for (immuno-) histological evaluation. Blood was collected by orbital 
puncture immediately following sacrifice and plasma was separated by centrifugation 
(5000 r/min for 5 min). Plasma samples were stored at −80°C until analysis. 
  




5.2.4 Histological analysis 
Colonic segments were fixed in 10% formalin overnight and thereafter stored 
in 70% ethanol before embedding in paraffin. Tissues sections (7 μm thick) were 
stained with haematoxylin for histology scoring. The histology damage score was 
calculated using the following criteria: percentage of area involved, number of follicle 
aggregates, edema, fibrosis, erosion/ulceration, crypt loss, and infiltration of 
mononuclear and polymorphonuclear cells, as described previously (312). The 
percentage of area involved and crypt loss were scored on a scale of 0–4 (0, normal; 
1, <10%; 2, 10%; 3, 10%–50%; and 4, >50%). Erosions were defined as 0 if the 
epithelium was intact, 1 if the lamina propria was involved, 2 if ulcerations involved 
the submucosa, and 3 when ulcerations were transmural. The severity of the other 
parameters was scored on a scale of 0–3 (0, absent; 1, weak; 2, moderate; and 3, 
severe) (312). A certified pathologist scored all the tissue sections (blinded analysis). 
 
5.2.5 Immunohistochemistry 
Colon tissues sections of 7 μm were aceton-fixed and stained with rat-anti-
mouse (rαm) CD4 (1:100, BD550278), rαm CD8a (1:50, BD550281), rαm CD19 
(1:50, BD550284), rαm Foxp3 (1:100, eBiosciences14-5773-82) and rαm F4/80 
(1:500). Prior to anti-rat biotin conjugated secondary antibody (1:50, BD51-7605kc) 
and Streptavidin-HRP (BD) incubations, endogenous peroxidases were blocked by 
incubation with 0.3% H202 for 20 minutes. After 5 min of DAB staining (BD), the 
sections were counter-stained with Haematoxylin, dehydrated and mounted in 
Entallan. 
 
5.2.6 Flow cytometry 
Thymus, mesenteric lymphoid nodes, liver and spleen tissue were collected 
upon sacrifice. Cell suspensions obtained from each of the tissue samples were 
prepared using 40 μm cell strainers (BD Biosciences) and stained for T cell surface 
markers CD4 (clone RM4-5, eBioscience), CD8 (Clone 53-6.7, Miltenyi) and Treg 
cell surface markers GARP and CD25 (clone YGIC86 and clone PC61.5 respectively, 
both eBioscience) as well as for the intracellular Treg cell marker Foxp3 (clone 
FJK16, eBioscience). The analysis was performed by flow cytometry (FACSCalibur, 
BD Biosciences).  
 
5.2.7 Statistical analysis 
The results are presented as means (+/- standard deviation (SD) or standard 
error of the mean (SEM), where appropriate). Statistical analyses were performed 
using Prism 5.0 (GraphPad). Data were analyzed using a 1 way ANOVA, followed by 
Dunn’s post hoc test for multiple comparisons. 
 
5.3 Results 
The potential for AAV5-mediated delivery of regulatory T-cell epitopes to 
prevent the development of TNBS induced colitis was investigated. Mice treated 
intra-rectally with TNBS in ethanol developed a severe illness as reflected in the 
progressive body weight loss over time and an increase in disease activity index, 
histology damage score and mucosal inflammatory parameters at the time of sacrifice. 
 




5.3.1 Tregitope 167 delivery protects against TNBS colitis development 
Development of colitis in the TNBS mice model is strongly associated with 
wasting disease (313). Daily weight determination is therefore important to determine 
colitis severity and is indicative of differences in colitis development between 
experimental groups (313). Animals were withdrawn from the study when their 
weight loss was >25% of their original body weight.  
The body weight of the mice was monitored daily after the first TNBS 
treatment as an indication of the severity in the colitis development between 
experimental groups (Figure 5.2). TNBS treated mice that were pre-administered 
with Tregitope 167, showed a body weight that increased over time and was 
comparable to the weight gain of untreated healthy control mice (Figure 5.2). The 
Tregitope 167 treated mice gained an average of 4% over their initial body weight at 
the time of sacrifice (Figure 5.3A). In contrast, the mice treated with TNBS alone (no 
Tregitope) developed colitis, and had lost 4% of their initial body weight at the time 
of sacrifice (Figure 5.3A).  
Increases in colon weight, as well as in the disease activity index are both 
indicative of colonic inflammation and were determined at the time of sacrifice 
(Figure 5.3). The body weight increase that had been observed in the mice pre-treated 
with Tregitope 167 was substantiated by a lower disease activity index (Figure 5.3B) 
and a decreased colon weight (Figure 5.3C) as compared to the diseased control 
group (P value <0.01 and <0.001 respectively). 
The histology damage score was performed on HE stained tissue sections. The 
score was calculated using the following criteria: percentage of area involved, number 
of follicle aggregates, edema, fibrosis, erosion/ulceration, crypt loss, and infiltration 
of mononuclear and polymorphonuclear cells. The histological scoring showed that 
the AAV5 (CMV-Tregitope 167) pre-treated mice presented a decreased severity of 
colitis as compared to the diseased control group (Figure 5.3D) as a result of lower 
levels of inflammation, namely decreased cellular infiltrations, little crypt loss and the 
absence of erosions and ulceration (Figure 5.4).  
The TNBS induced colitis model is characterized by the local infiltration of 
CD4+ T cells in the intestinal mucosa (314). Immunohistochemical staining of the 
colonic tissues for CD4+ showed that, at the day of sacrifice, inflammatory cell 
infiltrates were present in TNBS treated mice with or without administration with 
Tregitope 167 and that these cellular infiltrates consisted mainly of CD4+ cells. For 
both TNBS treated groups CD4+ T cell infiltrates were observed in the sub-epithelial 
layer and the lamina propria. CD4+ T cell infiltrates were also present in the 
muscularis mucosa layer of the diseased control mice, but were absent in the AAV5 















Figure 5.1 Schematic overview of the Trinitrobenzene sulfonate induced colitis 
model. Mice were injected intravenously with either PBS or AAV5 (CMV-Tregitope 
167). 10 d after AAV-mediated Tregitope delivery acute colitis was initiated by intra-
rectal administration of 1.5 mg TNBS in 40% ethanol followed by a second TNBS 
treatment (0.75 mg in 20% ethanol) 8 days later. Control groups consisted of mice not 







Figure 5.2 Adeno associated virus serotype 5 mediated delivery of regulatory T-
cell epitope 167 ameliorates Trinitrobenzene sulfonate induced colitis 
development over time. Mice were injected intravenously with either PBS or AAV5 
(CMV-Tregitope 167). 10 d after AAV-mediated Tregitope delivery, acute colitis was 
initiated by intra-rectal administration of 1.5 mg TNBS in 40% ethanol followed by a 
second TNBS treatment (0.75 mg in 20% ethanol) 8 days later. Control groups 
consisted of mice not treated by TNBS (healthy control group) and mice treated by 
TNBS only (diseased control group). Disease progression was assessed by changes in 
daily body weight. Animals were withdrawn from the study when their weight loss 
was >25% of their original body weight. Overall for the healthy controls, n = 9; 
AAV5 (CMV-Tregitope 167) treated, n=7; diseased controls, n=6, were included in 
the analysis. The data were analyzed using a 1 way ANOVA, followed by Dunn's post 
hoc test for multiple comparisons. Data are presented as means +/- SEM of all the 
mice. dP value <0.0001 between PBS (diseased control group) and both AAV5 
(CMV-Tregitope 167) treated and the healthy control group. PBS: Phosphate-buffered 
saline; TNBS: Trinitrobenzene sulfonate; AAV: Adeno-associated virus. 






Figure 5.3 Adeno associated virus serotype 5 mediated delivery of regulatory T-
cell epitope 167 alleviates colonic inflammation as determined at the day of 
sacrifice.  Mice were injected intravenously with either PBS or AAV5 (CMV-
Tregitope 167). 10 d after AAV-mediated Tregitope delivery acute colitis was 
initiated by intra-rectal administration of 1.5mg TNBS in 40% ethanol followed by a 
second treatment with TNBS (0.75mg in 20% ethanol) 8 days later. Control groups 
consisted of mice not treated by TNBS (healthy control group) and mice treated by 
TNBS only (diseased control group). Disease progression was assessed by changes in 
daily body weight as well as macroscopic and microscopic scores on the day of 
sacrifice. A: Animal body weight change on day 20 upon sacrifice. The values of 
body weight are expressed as a percentage of body weight on the day of the first 
TNBS treatment; B: Macroscopic disease score. The disease activity index (DAI) 
consist of a combination of body weight loss, loose stool and visible fecal blood 
scores divided by 3 at the day of sacrifice; C: Assessment of colonic weight upon 
sacrifice as an index of disease-related intestinal wall thickening; D: Histological 
grading of colonic colitis scores. The histology damage score was calculated using the 
following criteria: percentage of area involved, number of follicle aggregates, edema, 
fibrosis, erosion/ulceration, crypt loss, and infiltration of mononuclear and 
polymorphonuclear cells. Individual mice are depicted; from the AAV5 (CMV-
Tregitope 167) pre-treated group an outliner was removed. Animals were withdrawn 
from the study when their weight loss was >25% of their original body weight. 
Overall for the healthy controls, n = 9; AAV5 (CMV-Tregitope 167) treated, n=6; 
diseased controls, n=6, were included in the analysis. The data were analyzed using a 
1 way ANOVA, followed by Dunn's post hoc test for multiple comparisons. Data are 
presented as means +/- SD of all the mice. aP value <0.05, bP value, <0.01, cP value 
<0.001 vs PBS (diseased control group). PBS: Phosphate-buffered saline; TNBS: 












Figure 5.4 Hematoxylin and eosin-stained paraffin section from colon tissue. A, 
B: Healthy control mice; C, D: Diseased control mice; E, F: AAV5 (CMV-Tregitope 
167) pre-treated mice. Histological evidence that AAV5 (CMV-Tregitope 167) 
ameliorates TNBS-induced pathology. Images depicted of an HE-stained paraffin 
section of a representative mouse colon from each group at the moment of sacrifice. 
The images of the diseased control (C, D) demonstrated acute inflammation: 
elongated villi, abundant transmural cellular infiltrate, erosions and crypt loss as 
compared to both the AAV5 (CMV-Tregitope 167) pre-treated and healthy control 














Figure 5.5 Immunohistochemistry pictures depicting CD4 staining colon tissue. 
A, B: Healthy control mice; C, D: Diseased control mice; E, F: AAV5 (CMV-
Tregitope 167) pre-treated mice. Specific immunohistochemical staining showed 
inflammatory cell infiltrates present in TNBS treated mice with or without 
administration with Tregitope 167 consisted of CD4 positive cells, localized in the 
sub-epithelial layer, in the lamina propria (C-F) and for the diseased control also in 
the muscular layer (C,D). Depicted are representative data from a single mouse. 









5.3.2 Increase of regulatory markers expression in the intestinal mucosa and 
thymus of mice administered with Tregitope 167 
The reported ability of Tregitopes to both activate and induce Treg cells led us 
to further assess the presence of Treg-cell associated markers in the colonic tissues.  
Colon tissues were prepared and the presence of transcription factor Foxp3 
was assessed by immunohistochemistry, so as to determine whether regulatory T cells 
were present in the peri-colonic infiltrates (5). Numerous Foxp3 positive cells were 
detected in the lamina propria and sub-epithelium of the colon sections from mice 
treated with Tregitope 167 (Figure 5.6). Foxp3 positive cells were absent or sporadic 
in the colon of healthy and diseased control mice (Figure 5.6). 
Thymus, mesenteric lymph nodes, liver and spleen tissue were collected at the 
time of sacrifice and the corresponding lymphocyte populations were further assessed 
by flow cytometry analysis for the expression of the CD4 T cell surface marker and 
the Treg cell associated markers Foxp3 (108), CD25 (315) and GARP (316;317). The 
Foxp3 and GARP markers were significantly increased in the CD4+ T lymphocyte 
population in the thymus of the mice pre-treated with AAV5 (CMV-Tregitope 167), 
as compared to lymphocyte populations in the thymus of diseased and the healthy 
control mice (P value <0.05 and <0.001 respectively, Figure 5.7). CD4+ thymic 
lymphocyte population (mean ± SD, 11% ± 2%, n=6) co-expressed Foxp3 and GARP 
in the thymus of AAV5 (CMV-Tregitope 167) pre-treated mice as compared to the 
thymic lymphocyte population of diseased (mean ± SD, 7% ± 3%, n=6) and the 
healthy control groups (mean ± SD, 6% ± 2%, n=9), respectively (Figures 5.7 and 
5.8). Both the relative and absolute number of Foxp3 expressing T cells were 
expanded in the thymus after AAV5 (CMV-Tregitope 167) pre-treatment (Figure 
5.9). No significant differences in the expression of Foxp3 and GARP in the 
lymphocyte populations of the mesenteric lymph nodes, liver and spleen were 
identified. 
  








Figure 5.6 Immunohistochemistry pictures depicting Forkhead Box-P3 staining 
colon tissue. A, B: Healthy control mice; C, D: Diseased control mice; E, F: AAV5 
(CMV-Tregitope 167) pre-treated mice. Colon tissue were prepared and assessed by 
immunohistochemistry for the expression of the transcription factor Foxp3 as a 
marker for regulatory T cells. Numerous Foxp3 positive cells were detected in the 
lamina propria and sub-epithelium of the colon sections from mice treated with 
Tregitope 167 (E, F). Foxp3 positive cells were rarely present in the colon of healthy 
and diseased control mice (A-D). Depicted are representative data from a single 
















Figure 5.7 Adeno associated virus serotype 5 mediated delivery of regulatory T-
cell epitope 167 induces Forkhead Box-P3 and GARP expression in the CD4 
positive thymic lymphocyte population. Thymus tissue was collected upon 
sacrifice. Cells suspensions were prepared and stained for the following markers: 
CD4, GARP and Foxp3 before analysis by flow cytometry (FACSCalibur, BD 
Biosciences). Depicted are percentages of CD4 positive, Foxp3 positive and GARP 
positive thymic lymphocytes. Individual mice are depicted; for the AAV5 (CMV-
Tregitope 167) pre-treated group one mouse did not have a thymus and therefore n=6 
mice were included in this analysis. The data were analyzed using a 1 way ANOVA, 
followed by Dunn's post hoc test for multiple comparisons. Data are presented as 
means +/- SD of all the mice. aP value <0.05, bP value, <0.01, cP value <0.001 vs PBS 











Figure 5.8 Adeno associated virus serotype 5 mediated delivery of regulatory T-
cell epitope 167 induces Forkhead Box-P3 and GARP expression in the CD4 
positive thymic lymphocyte population. Thymus tissue was collected upon 
sacrifice. Cells suspensions were prepared and stained for the following markers: 
CD4, GARP and Foxp3 before analysis by flow cytometry (FACSCalibur, BD 
Biosciences). A: Histogram Foxp3 cell count: healthy control; C: Histogram Foxp3 
cell count: diseased control; E: Histogram Foxp3 cell count: AAV5 (CMV-Tregitope 
167) pre-treated group (grey, filled in) versus unstained control (black continuous 
line). Gating was done on the CD4 positive thymic lymphocyte population. Depicted 
are representative data from a single mouse; B: Histogram GARP cell count: healthy 
control; D: Histogram GARP cell count: diseased control; F: Histogram GARP cell 
count: AAV5 (CMV-Tregitope 167) pre-treated group (grey, filled in) versus 
unstained control (black continuous line). Gating was done on the CD4 positive 
thymic lymphocyte population. Depicted are representative data from a single mouse.  








Figure 5.9 relative and absolute number of Foxp3 expressing T cells in the 
thymus. 
Both the relative and absolute number of Foxp3 expressing T cells were expanded in 
the thymus after AAV5 (CMV-Tregitope 167) pre-treatment. 
 
 





Curative treatment approaches for Crohn's disease and ulcerative colitis 
represent a significant unmet medical need. Regulatory T (Treg) cells are key players 
in maintaining peripheral tolerance, preventing autoimmune diseases and limiting 
chronic inflammation (5;6). Therefore, novel strategies that aim for therapeutic 
tolerance induction and leverage Treg cells are currently being explored (192). In the 
present study, the potential for AAV-mediated delivery of an immunomodulatory 
peptide (Tregitope 167) was investigated.  
In this study, it was demonstrated that the systemic AAV-based delivery of 
Tregitope 167 has the potential to prevent the development of fulminant colitis in a 
TNBS-induced model of IBD. Tregitope 167 was used in our study as its binding 
affinity for the MHC molecule in Balb/c mice is superior to Tregitope 289 (De Groot, 
manuscript submitted for publication). The significant decrease of colonic 
inflammation in the Tregitope 167 pre-treated mice was reflected in an overall weight 
gain and substantiated by a decreased disease activity index, colon weight and 
histology damage score at the time of sacrifice. Additionally, there was less mucosal 
inflammation in the AAV (CMV-Tregitope 167) pre-treated mice. This therapeutic 
benefit corresponded with increases in the relative number of T cells expressing 
regulatory T cell markers in the colon tissues and among thymic lymphocytes of the 
Tregitope 167-treated mice. 
IBD patients do not present defects in regulatory T cell function or phenotype 
(196;199;318) and by consequence are more likely to benefit from therapies aiming at 
inducing and expanding Treg cells than patients affected by other autoimmune 
diseases. Tregitope 167 has the potential to both activate nTreg cells and induce iTreg 
cells (211;307) and may be suitable as a novel therapeutic agent for IBD. However, 
the use of immunomodulatory peptides in clinical applications for IBD has been 
hindered by difficulties associated with the systemic delivery of the therapeutic 
peptides in sufficient quantity and concentration to the target tissues (157-159). AAV 
has proven to be both effective and safe as a gene therapy delivery vector in the clinic 
(88;90;161). Therefore, AAV-mediated delivery of Tregitopes was explored in this 
study. The AAV serotype 5 (AAV5) was used since pre-existing immunity to AAV5 
in humans has been shown to be low (171;311). Our data demonstrate that AAV5-
mediated delivery may be an efficient approach for stable administration of 
Tregitopes in vivo. Further studies will need to be performed to determine the duration 
of the immunological tolerance that is evoked by induction and activation of Treg 
cells.  
Regulatory T (Treg) cells are considered to be essential in the counter-
regulation of inflammatory reactions and Foxp3 is considered as a marker of the 
regulatory phenotype (108;109;128). Staining for Foxp3 in mice pre-treated with 
Tregitope 167 revealed the presence of Foxp3 positive cells in the lamina propria and 
sub-epithelium of the colon sections. Additionally, expression of both Foxp3 and 
GARP were increased in the thymic CD4+ T lymphocyte population in mice pre-
treated with AAV5 (CMV-Tregitope 167), indicating an increase in activated 
regulatory T-cells (108;109;128;316;317). The presence of higher numbers of 
activated regulatory T cells corresponded with the prevention of fulminant intestinal 
inflammation in vivo in this TNBS model of IBD.  
No increase in the Treg cell populations was observed in the mesenteric lymph 
nodes, liver and spleen in the current study. We hypothesize that this could be due to 
the duration of the experiment and the timing of the Treg cell evaluation. In other 
mouse models such as the model of spontaneous encephalomyelitis, the de novo 




generation of Treg cells was initiated intrathymically, and was followed by Foxp3 
induction in peripheral tissue at later time points (319). 
Tregitopes are T cell epitopes, naturally located in immunoglobulins, which 
bind to multiple MHC Class II alleles and induce Treg cell responses. It was 
demonstrated that antigen presenting cells (APCs) present Tregitopes to nTreg cells, 
engage feedback mechanisms promoting a tolerogenic APC phenotype, induce Treg 
cell expansion and modulate antigen-specific effector T cell responses (Cousens and 
De Groot, manuscript submitted for publication). Proportions of APC expressing 
MHC II, CD80, and CD86 are suppressed, consistent with reported effects of 
Intravenous immunoglobulin (IVIG) (320) and of the immunoglobulin (Ig) G-derived 
peptide hCDR1 (321). The basic mechanism of Tregitope tolerance induction is 
currently proposed to be as follows: 1) APC present Tregitopes to nTreg cells, 2) 
nTreg cells are activated to proliferate, 3) nTreg cells provide tolerogenic feedback 
signals to APC, modulating the APC phenotype, and 4) nTreg cells and tolerogenic 
APC together suppress antigen-specific T cell responses (Cousens and De Groot, 
manuscript submitted for publication). 
A limitation of the colitis model used in this study was the acute necrotizing 
enterocolitis, occurring in the first 3 days after the first TNBS treatment, a 
presentation of disease which is unrelated to IBD (309). Therefore the surviving 
number of mice, included in the analysis was lower than anticipated, which, for some 
analysis, conflicted with statistical analysis of the data. As a consequence, a large 
variability in the colon mucosa cytokines levels was observed after TNBS induced 
experimental colitis and prevented an accurate analysis of those parameters. 
Therefore, further development of AAV mediated delivery of Tregitope 167 in 
different experimental models of inflammatory disease will be necessary to confirm 
the obtained results. 
In summary, our data provide preliminary evidence supporting the potential 
use of AAV-based Tregitope delivery as a therapy for the treatment of IBD. Further 
investigations will permit to define the mechanism by which Tregitope exert their 
immune regulatory properties, the duration of the effect, the ability of Tregitopes to 
reduce disease that has already been established and their eventual impact on systemic 
immunity.  
Overall, this study identifies AAV-mediated delivery of regulatory T-cell 
epitope 167 as a novel anti-inflammatory approach with the capacity to decrease 
intestinal inflammation and induce long-term remission in IBD. 
  
  




Chapter 6  
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Recombinant adeno-associated viral vectors (AAV) have shown great promise 
for gene therapy in a variety of different disorders (1-3). However, one major 
challenge for a successful administration of AAV vectors is the presence of 
neutralizing antibodies (nAb) that are developed against the AAV capsid after 
exposure to the wild type AAV or after the first AAV vector administration. The 
neutralizing serotype-specific antibodies directed towards the viral capsid proteins 
will prevent efficient gene transfer with recombinant AAV (rAAV) of the same 
serotype (322). 
The impact of the presence of specific nAb in the plasma on AAV-based gene 
delivery, needs to be addressed. For that purpose, we have established an in vivo 
model of nAb passive transfer to determine the threshold of nAb titers compatible 
with an efficient AAV transduction. The model was set-up for both C57BL/6 
immuno-competent mice and NOD-SCID immuno-deficient mice. 
 
6.2 Material & methods  
 
6.2.1 AAV vector production and characterization 
An AAV serotype 5 (AAV5) vector containing the transgene GFP under the 
control of the EalbhAAT liver specific promoter (AAV5-hAAT-GFP) was produced 
and purified (294). The presence of AAV capsid proteins (VP1, VP2 and VP3) was 
determined by polyacrylamide gel electrophoresis and the concentration of vector 
genomes (gc/ml) was determined by qPCR. 
 
6.2.2 Virus neutralizing assay 
HEK293 cells were seeded in a 96 well plate (Corning) coated with 0.25% 
poly L-lysine at 1 x105cells/well in 100μl medium (DMEM/10%FBS/0.5%Pen Strep). 
Cells were incubated overnight at 37°C.  
The following day, serial dilutions of test plasma; 1:10, 1:20, 1:40, 1:80, 
1:160, 1:320, 1:640, and 1:1280 were prepared in medium without FBS. All the test 
sample mixes were incubated for 1 hour at 4°C. After the 1 hour incubation, medium 
was removed from the HEK cells and the test plasma mixes were added and incubated 
at 37°C overnight. 
Following the overnight incubation, the cells were washed with PBS and 
collected after trypsinisation. GFP expression of the cells was analyzed by flow 
cytometry (FACScalibur, Becton Dickinson) in channel FL1 at a wavelength of 530 
nm. The data analysis was performed with Cellquest software.  
The percentage of inhibition was calculated in relation to GFP expression 
measured in rAAV5 HEK293 infected cells (no inhibition, 100% expression). Plasma 
samples were considered to have neutralizing activity if the lowest plasma dilution 
inhibited vector transduction by at least 50%, as described before (170-172;311). 
 
6.2.3 in vivo nAb passive transfer 
C57BL/6 mice (males, age 6-8 weeks) and NOD-SCID mice (males, age 6-8 
weeks) were obtained from Harlan Laboratories, the Netherlands (n=6 per group). 
The experimental protocol was approved by the local ethical committee for animal 
welfare of the AMC (Academic Medical Center, Amsterdam, the Netherlands).  
C57BL/6 immuno-competent mice and NOD-SCID immuno deficient mice 
were used in parallel in the study (see: Figure 6.1). The NOD-SCID mice model was 
developed to allow future plasma transfer experiments in mice recipient with human 
plasma. 




C57BL/6 mice and NOD-SCID mice (n=6/group) were injected intravenously 
with undiluted mouse plasma containing anti-AAV5 nAb (high titer, i.e. 1280) or PBS 
followed by AAV5 (hAAT-GFP) or PBS (see: Figure 6.1). 
Alternatively, mice (n=6/group) were injected intravenously with serial 
dilutions of plasma containing anti AAV5 nAb (1:3, 1:10 and 1:20) or PBS followed 
by AAV5 (hAAT-GFP) or PBS (see: Figure 6.1). 
In order to monitor the circulating anti AAV5 nAb levels, blood samples were 
collected weekly from the mice by submandibular vein puncture in tubes containing 
2μl of heparin/PBS. Plasma was isolated after centrifugation for 5 min at 5000 rpm 
and frozen at -80°C until further analysis. 
 
6.2.4 Tissue processing 
Mouse liver tissues were collected at sacrifice. Liver tissue samples were both 
snap frozen in liquid nitrogen for microscopic evaluation and DNA isolation and 
collected in medium, for cell preparation and evaluation by flow cytometry. Cryo-
sections of snap frozen liver tissue were cut (7 μm thick) for fluorescent microscopic 
analysis. Genomic DNA was isolated from the remaining snap frozen liver tissue, 
using the Gentra pure gene tissue kit (Qiagen), according to the manufactures 
protocol. Cell suspensions were prepared from the liver tissue, using 40μm cell 
strainers (BD Biosciences) for flow cytometry, directly after sacrifice of the mice.  
 
6.2.5 Flow cytometry 
GFP expression in hepatocytes was monitored by flow cytometry 
(FACScalibur, Becton Dickinson) in channel FL1 at a wavelength of 530 nm. The 
data analysis was performed with the Cellquest software. 
 
6.2.6 qPCR 
The number of genome copies (gc) per milliliter (ml) of GFP coding sequence 
was measured by TaqMan Quantative Polymerase Chain Reaction (Q-PCR). GFP 
specific primers and probe were used for the analysis (forward primer 798: 5’-
AGCAAAGACCCCAACGAGAA-3’; reversed primer 799: 5’-
GCGGCGGTCACGAACTC-3’; Probe 19- CGCGATCACATGGTCCTGC). 
Amplifications were carried out on 250 ng of DNA in a total volume of 20μl 
containing qPCR mix (TaqMan® Fast Universal PCR Master Mix, life technologies). 
Samples were run in duplicates. 
 
6.2.7 Statistical analysis 
Results are presented as means (+/- standard error of the mean, SEM). 
Statistical analyses were performed using Prism 5.0 (GraphPad). Data were analyzed 
using a 2 ways ANOVA, followed by Bonferroni post hoc test for multiple 
comparisons. 
  






6.3.1 Establishment of an anti-AAV5 nAb passive transfer model in C57BL/6 
and NOD-SCID mice 
Both C57BL/6 and NOD-SCID mice were injected with plasma containing 
anti-AAV5 nAb, or with PBS prior injection with AAV5 (EalbhAAT-GFP). For both 
animal models no toxicity was observed after plasma transfer.  
 
 6.3.1.1 C57BL/6 mice model 
One hour after intravenous injection of plasma containing anti-AAV5 nAb (initial 
titer 1280) in C57BL/6 mice, an anti-AAV5 nAb titer, of approximately 10% of the 
initial nAb titer injected was measured in the plasma of the mice (final titer 140, SEM 
20, n=10, see Table 6.1A). Consequently, a 3 times pre-dilution of plasma containing 
nAb resulted in a final 1:30 dilution upon transfer in vivo (mean titer 10, SEM 0, n=5, 
Table 6.1B). Further pre-dilution of the plasma, at final dilutions of 1:100 and 1:200, 
resulted in titers of anti-AAV5 circulating nAb that could not be detected in our virus 
neutralizing assay (Table 6.1B). Two hours after injection with either plasma or PBS, 
mice (n=6/group) were injected intravenously by tail-vein injection with AAV5 
(EalbhAAT-GFP) (see: Figure 6.1). The anti-AAV5 nAb level in the immune-
competent C57BL/6 mice was sustained over time as a result of an endogenous 
humoral immune response against AAV5 (EalbhAAT-GFP) (mean titer 232, SEM 
113, see: Figure 6.2A and 6.3A and Table 6.1A-B). In the mice pre-injected with 
PBS, the anti-AAV5 nAb response developed against AAV5 (EalbhAAT-GFP) 
resulted in a high anti-AAV5 nAb titer (mean nAb titer 1280, SEM 0, after 14 days). 
The difference in nAb titer between the two groups can be explained by the fact that 
the transferred, exogenous nAb bind to the capsid of a large part of the injected AAV 
particles before the endogenous humoral immune response can be initiated. This 
partly prevents transduction and thereby a fulminant humoral immune response as is 
seen in the PBS pre-treated control group. 
 
6.3.1.2 NOD-SCID mice 
One hour after intravenous injection of plasma containing anti-AAV5 nAb 
(initial Titer 1280) injection in the NOD-SCID mice, an anti AAV5 nAb titer of 
approximately 2.5% of the initial anti-AAV5 nAb titer was measured in the plasma of 
the mice (mean titer 32, SEM 5, n=10, see: 1 hour time point Table 6.2A). The final 
titer of circulating anti-AAV5 nAb was 5 times lower as compared to the C57BL/6 
mice. This observation is related to circulating blood volume which was different 
between these two mice strains. The NOD-SCID mice weigh more than the C57BL/6 
mice in these experiments, have more circulating volume and therefore a higher 
diluting factor of the injected nAb titer, which accounts for the differences in obtained 
titer after injection. 
As the NOD-SCID mice lack B-cells, no endogenous adaptive immune-
response to the AAV5 capsid was initiated after AAV5-haat-GFP delivery.  In this 
mice model, the anti-AAV5 nAb injected decreased over time and could not be 
detected after 14 days in the blood of NOD-SCID mice (see: Figure 6.2B and 6.3B 
and Table 6.2A-B).  
 





Figure 6.1 Experimental set-up 
 
 
Figure 6.2 nAb against the AAV5 vector capsid, set-up experiments 
A. BL6 mice and B. NOD-SCID mice. 






Figure 6.3 nAb against the AAV5 vector capsid, titration experiments 
A. BL6 mice and B. NOD-SCID mice.  
 
6.3.2 Role of preexisting anti-AAV5 neutralizing antibodies on AAV5 mediated 
liver transduction  
The efficacy of AAV5 (EalbhAAT-GFP) vector transduction was determined 
by monitoring: i) the GFP expression by fluorescent microscopy (see: Figure 6.4), ii) 
the GFP expression by flow cytometry (see: Figure 6.5) and iii) the presence of the 
AAV vector DNA in liver tissue by qPCR (see: Table 6.3 and 6.4). 
  




6.3.2.1 C57BL/6 mice 
GFP expression was detected by microscopic fluorescence in liver tissues of 
mice pre-injected with PBS, but could not be detected in mice pre-injected with 
plasma containing anti-AAV5 nAb (see: Figure 6.4). Even the lowest titer of anti-
AAV5 nAbs (10), was associated with a level of GFP protein expression that could 
not be detected by fluorescent microscopy on liver tissue sections (see: Figure 6.4B). 
Further analyses to detect GFP expression in liver cells were performed by 
flow cytometry. In the PBS pre-treated mice a mean of 6% of the cells were shown to 
express GFP while only a mean of 2% of the cells expressed GFP after pre-treatment 
with plasma containing anti-AAV5 nAb. This result indicates that a reduction in the 
number of cells expressing GFP is observed in presence of anti-AAV5 nAb at titer as 
low as 10, i.e. the lowest titer which can be measured with the nAb assay (see: Figure 
6.5A). 
The presence of vector DNA in the liver cells was further monitored by qPCR 
analysis. The presence of AAV5 vector DNA was detected by flow cytometry in both 
tissues where GFP expression was present or absent. Although variability between 
samples occurred within the results obtained by qPCR (see: Table 6.3), up to 6 times 
more AAV5 vector DNA could be detected in the PBS pre-treated mice compared to 






Figure 6.4 Microscopy liver tissues 
BL6 mice, representative slides depicted. 
 






Figure 6.5 flow cytometry liver tissue 
A. BL6 mice and B. NOD-SCID mice. 
 
 
6.3.2.2 NOD-SCID mice 
Analyses were performed by flow cytometry to detect GFP expression in liver 
cells. In the PBS pre-treated mice a mean of 2% of the cells were shown to express 
GFP as compared to a mean of  1% of the cells in the anti-AAV5 nAb pre-treated 
mice which represents a 2x reduction in GFP expression after anti-AAV5 nAbs pre-
treatment (see: Figure 6.5B).  
The presence of the vector DNA in the liver was further monitored by qPCR 
analysis. Comparable to the results obtained in the C57BL6 mice model, AAV vector 
DNA was detected in the tissues of the NOD-SCID mice where no GFP could be 
detected (see: Table 6.4). Despite some variability in the qPCR results, up to 6 times 
more AAV vector DNA could be detected in the PBS pre-treated mice as compared to 
the anti-AAV5 nAb pre-treated mice (see: Table 6.4B).  
 
  




 PBS + AAV nAb 1:10 + AAV nAb 1:10 only 
Time point Mean titer SEM N Mean titer SEM N Mean titer SEM N 
Baseline 0 0 6 0 0 6 0 0 6 
1 hour 0 0 5 140 20 4 140 20 6 
7 days 960 185 4 72 23 5 50 10 6 
14 days 1280 0 5 232 113 5 30 4 6 
21 days 1152 128 5 152 48 5 5 2 6 
 
Table 6.1A BL6 set-up experiments 
Mean titer nAb against AAV vector capsid generated by nAb containing plasma 
transfer, followed by liver directed, intravenous AAV5 (EalbhAAT-eGFP) injection. 
 
 
 PBS + AAV nAb 1:200 + AAV nAb 1:100 + AAV 
Time point Mean titer SEM N Mean titer SEM N Mean titer SEM N 
Baseline 0 0 6 0 0 6 0 0 6 
1 hour 0 0 6 0 0 6 0 0 6 
7 days 40 0 5 40 0 4 25 5 4 
14 days 40 0 4 43 8 6 23 3 6 
21 days 47 7 6 37 3 6 30 4 6 
 
 nAb 1:30 +AAV nAb 1:10 + AAV 
Time point Mean titer SEM N Mean titer SEM N 
Baseline 0 0 6 0 0 6 
1 hour 10 0 5 40 0 5 
7 days 15 3 4 3 3 4 
14 days 18 3 4 4 2 5 
21 days 22 5 5 10 3 6 
 
Table 6.1B BL6 titration experiments  
Mean titer nAb against AAV vector capsid generated by nAb containing plasma 
transfer, followed by liver directed, intravenous AAV5 (EalbhAAT-eGFP) injection. 
  




 PBS + AAV nAb 1:10 + AAV nAb 1:10 only 
Time point Mean titer SEM N Mean titer SEM N Mean titer SEM N 
Baseline 0 0 6 0 0 6 0 0 6 
1 hour 0 0 4 33 4 6 30 6 4 
7 days 0 0 4 0 0 3 6 2 5 
14 days 0 0 6 0 0 5 0 0 5 
21 days 0 0 6 0 0 6 0 0 6 
 
Table 6.2A NOD-SCID set-up experiments 
Mean titer nAb against AAV vector capsid generated by nAb containing plasma 
transfer, followed by liver directed, intravenous AAV5 (EalbhAAT-eGFP) injection. 
 
 PBS + AAV nAb 1:200 + AAV nAb 1:100 + AAV 
Time point Mean titer SEM N Mean titer SEM N Mean titer SEM N 
Baseline 0 0 6 0 0 6 0 0 6 
1 hour 0 0 6 0 0 6 0 0 5 
7 days 0 0 5 0 0 4 0 0 6 
14 days 0 0 6 0 0 4 0 0 6 
21 days 0 0 6 0 0 6 0 0 6 
 
 nAb 1:30 +AAV nAb 1:10 + AAV 
Time point Mean titer SEM N Mean titer SEM N 
Baseline 0 0 6 0 0 6 
1 hour 10 0 5 40 0 5 
7 days 0 0 4 0 0 4 
14 days 0 0 4 0 0 4 
21 days 0 0 6 0 0 6 
 
Table 6.2B NOD-SCID titration experiments  
Mean titer nAb against AAV vector capsid generated by nAb containing plasma 
transfer, followed by liver directed, intravenous AAV5 (EalbhAAT-eGFP) injection. 
  




 PBS + AAV nAb 1:10 + AAV nAb 1:10 only 
 Mean SEM N Mean SEM N Mean  SEM N 
GFP DNA 106850 22108 4 288275 73555 4 2209 490 6 
 
Table 6.3A BL6 set-up experiments 
Mean GFP DNA (in genome copies per ml) after by nAb containing plasma transfer, 
followed by liver directed, intravenous AAV5 (EalbhAAT-eGFP) injection. 
 
 PBS + AAV nAb 1:200 + AAV nAb 1:100 + AAV 
 Mean  SEM N Mean  SEM N Mean SEM N 
GFP DNA 267167 72074 6 42040 8588 5 92520 25098 5 
 
 
 nAb 1:30 +AAV nAb 1:10 + AAV 
 Mean SEM N Mean SEM N 
GFP DNA 154680 58309 5 181020 113241 5 
 
Table 6.3B BL6 titration experiments  
Mean GFP DNA (in genome copies per ml) after by nAb containing plasma transfer, 
followed by liver directed, intravenous AAV5 (EalbhAAT-eGFP) injection. 
  




 PBS + AAV nAb 1:10 + AAV nAb 1:10 only 
 Mean  SEM N Mean  SEM N Mean  SEM N 
GFP DNA 225000 50744 6 115400 81219 4 138043 129034 3 
 
Table 6.4A NOD-SCID set-up experiments 
Mean GFP DNA (in genome copies per ml) after nAb containing plasma transfer, 
followed by liver directed, intravenous AAV5 (EalbhAAT-eGFP) injection. 
 
 PBS + AAV nAb 1:200 + AAV nAb 1:100 + AAV 
 Mean SEM N Mean SEM N Mean SEM N 
GFP DNA 181700 55476 5 48017 8723 6 44180 13617 5 
 
 nAb 1:30 +AAV nAb 1:10 + AAV 
 Mean SEM N Mean  SEM N 
GFP DNA 82400 21503 5 29860 11016 5 
 
Table 6.4B NOD-SCID titration experiments  
Mean GFP DNA (in genome copies per ml) after nAb containing plasma transfer, 
followed by liver directed, intravenous AAV5 (EalbhAAT-eGFP) injection.  
 
 
6.4 Conclusions  
The presence of anti-AAV5 nAb was shown to decrease AAV5-mediated 
transgene delivery to the liver in both models. When circulating nAb against the AAV 
capsid are present, these bind and capture the AAV vector, thereby preventing 
transduction. Fewer vectors available for transduction will result in less protein 
expression and therefore will lower the delivery capacity of the AAV vector for gene 
therapy purposes. This chapter describes the establishment of two in vivo study  
models to test the influence of pre-existing circulating anti-AAV5 nAb on the efficacy 
of AAV5 vector transduction  to the liver. The NOD-SCID mice model was 
developed to allow future experiments with plasma samples of different species, i.e. 
to study human serum samples in vivo.  
In these studies we used GFP as a reporter gene to monitor AAV5 
transduction efficacy. GFP is a good and validated reporter protein. However, there is 
a limit of detection for GFP, i.e. microscopic detection of GFP lacks sensitivity to 
detect low levels of transduction, using a fluorescents based method. Furthermore, for 
the detection of GFP an experiment will need to be terminated to allow for the 
evaluation of GFP expression in the tissues. For future experiments, alternative 
proteins will be considered. Using a secreted protein as for example SEAP (secreted 
alkaline phosphatase) could have additional value in future studies, as it would allow 
for a more sensitive quantification of the efficacy of AAV vector based gene 
targeting. As SEAP is a secreted reporter protein it can easily be measured in the 
plasma by ELISA. It would therefore allow follow up of transduction efficacy on 
multiple time points, by analyzing serum samples without the need to terminate the 
experiment. 
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Recombinant adeno-associated viral vectors (AAVs) show great promise for 
gene therapy in a variety of different genetic disorders (91;161;323). AAV vectors 
have an excellent safety profile, as demonstrated in numerous non-clinical and clinical 
studies (324;325). Furthermore, AAV vectors were shown to mediate a stable 
therapeutic transgene expression in several non-clinical studies (323;326-329) and 
more recently in clinical studies (92;330-332). However, the majority of the 
transgenic proteins are expressed by episomally retained double stranded genomes 
that persist in post-mitotic tissues (333). This characteristic raises the possibility that 
transgene expression will decline overtime with the natural turnover of the transduced 
cells. Therefore, repeated administration may become necessary to maintain 
expression of the transgenic protein within therapeutic levels. One major challenge for 
a successful re-administration of AAV vectors is the presence of neutralizing 
antibodies (nAb) that are developed after the first administration. Those neutralizing 
serotype-specific antibodies, directed towards the viral capsid proteins, prevent 
efficient gene transfer with rAAV of the same serotype (334;335). Therefore, the 
generation of a humoral immune response does not permit the use of a “vector of 
choice” more than once, which is a concern for life–long disorders, for which re-
administration has to be considered. Hence strategies to decrease existing anti-AAV 
nAb titers need to be explored. 
Bortezomib, a selective inhibitor of the 26S proteasome (176;177) has been 
shown to significantly decrease AAV specific humoral immune responses after AAV-
based gene delivery in mice (178). However, this inhibition was only partially 
effective and insufficient to allow subsequent re-administration with a recombinant 
AAV vector of the same serotype (178). This limitation was shown to be due to the 
combination of residual antibody levels and the inability of Bortezomib to completely 
deplete the memory B cells (178). 
In this chapter, the potential of a poly-therapy combining Bortezomib with an 
anti-CD20 monoclonal antibody, targeted against pre-B cells, mature B cells and 
memory B cells (179;180), to reduce efficiently AAV specific nAb, thereby enabling 
AAV vector re-administration was explored. Additionally, the efficacy of the 
combined immunosuppressive regimen on the antibody response against the 
immunogenic protein ovalbumine (OVA) as a transgene delivered by AAV was 
monitored. 
  




7.2 Results & Discussion 
 
7.2.1 Experimental set-up 
Mice were injected intramuscularly with 1x1013gc/kg of AAV1 (CMV-OVA) 
or PBS. All the mice were followed for 21 days (3 weeks) for the development of nAb 
against the AAV1 capsid and antibodies against OVA transgene product. From day 
22, immunosuppressive (IS) therapy was initiated for 2 weeks, mono-therapy with 
Bortezomib or anti-CD20, and poly-therapy with both Bortezomib and anti-CD20 
(Figure 7.1). The drugs were administered three times intravenously at a dose of 
0.75mg/kg for the Bortezomib (day 28, 33 and 36 of the experiment) and two times 








7.2.2 Humoral response against OVA 
To assess the influence of Bortezomib and anti CD20 on the humoral immune 
response against the OVA transgene, the levels of specific anti- OVA antibodies 
generated were measured over time (Figure 7.2 A-C). The data obtained show a 
significant inhibitory effect of Bortezomib (67.19 % on day 28 and 71.18 % on day 
35) (Figure 7.3) and anti-CD20 ( 61.51 % on day 28 and 44. 38 % on day 35) (Figure 
7.3) on the humoral response raised against the OVA protein when compared to the 
control without IS. No significant additive inhibitory effect on anti-OVA antibody 
level was observed when anti-CD20 and Bortezomib treatment were combined 
(Figure 7.2 C). The inhibitory effect of the IS treatment on the humoral response was 
transient as the antibodies level increased at day 42 of the experiment (Figure 7.2 A-
C). 
 







Figure 7.2 to assess the influence of Bortezomib and anti CD20 on the humoral 
immune response against the OVA transgene, the levels of specific anti- OVA 
antibodies generated, were assessed over time 







Figure 7.3 to assess the influence of Bortezomib and anti CD20 on the humoral 
immune response against the OVA transgene, the levels of specific anti- OVA 
antibodies generated, were assessed at day 28 and 35. The data obtained show a 
significant inhibitory effect of Bortezomib (67.19 % on day 28 and 71.18 % on day 
35) and anti-CD20 (61.51 % on day 28 and 44. 38 % on day 35) on the humoral 
response raised against the OVA protein when compared to the control without IS. *P 
value <0.05, **P value, <0.01, ***P value <0.001, ***P value <0.0001 vs AAV (CMV-
OVA). 
  




7.2.3 Humoral response against AAV1- Neutralizing antibodies (nAb) against the 
AAV1 vector capsid 
To determine the effect of Bortezomib and anti-CD20 on the levels of 
neutralizing antibodies against the AAV1 viral capsid, a neutralizing antibody assay 
was performed on mice plasma samples obtained at days 0, 14, 28, 42, 56 and 84 
(Figure 7.4). After Bortezomib administration (days 28, 33 and 36), a decrease was 
observed in the levels of the nAb titers against the AAV1 capsid at days 42 (13.6%), 
56 (26.3%) and 84 (38.7%) when compared to the control without IS (Figure 7.4A). 
After anti-CD20 administration (days 22, and 27), a decrease was observed in the 
levels of the nAb titers against the AAV1 capsid (day 84) when compared to the 
control without IS (35.5%) (Figure 7.4B). The delayed response to the anti-CD20 
antibody treatment is consistent with the mechanism of action of this antibody (336).  
The combination of both IS drugs did not show an additive effect on the reduction of 
anti-AAV1 nAb levels (Figure 7.4C). The effect of the IS treatment on the humoral 
response was sustained until the end of the observation period, as the neutralizing 
antibodies levels remained low until day 84 for both Bortezomib and anti CD-20. 
However, the anti-AAV nAb titer obtained after treatment (a titer of 2592) was not 
low enough to perform re-administration, as previously reported (178).  
 We conclude that a combined treatment with Bortezomib and anti-CD20 
antibody, when a high titer (~3550) of anti-AAV1 nAb has already been established, 
cannot reduce the level of those antibodies sufficiently to permit re-administration. 
Therefore other combination of treatments that include additional cellular targets 
should be explored in the future. 
 






Figure 7.4 to determine the effect of Bortezomib and anti-CD20 on the levels of 
neutralizing antibodies against the AAV1 viral capsid, a neutralizing antibody assay 
was performed on mice plasma samples obtained at days 0, 14, 28, 42, 56 and 84. 
After Bortezomib administration (days 28, 33 and 36), a decrease was observed in the 
levels of the nAb titers against the AAV1 capsid at days 42 (13.6%), 56 (26.3%) and 
84 (38.7%) when compared to the control without IS. After anti-CD20 administration 
(days 22, and 27), a decrease was observed in the levels of the nAb titers against the 
AAV1 capsid (day 84) when compared to the control without IS (35.5%). The 
combination of both IS drugs did not show an additive effect on the reduction of anti-
AAV1 nAb levels. The effect of the IS treatment on the humoral response was 




sustained until the end of the observation period as the neutralizing antibodies levels 




No weight loss or signs of illness were observed in the mice receiving the 
immunosuppressive drugs alone or in combination. 
It has been described previously that a dose of 1 mg/kg Bortezomib was 
associated with toxicity in 15% of the animals treated (178), suggesting a narrow 
therapeutic window of this drug. We report that administration of a dose of 0.75mg/kg 
Bortezomib associated or not with anti-CD20 (100 μg per injection) did not appear to 
induce toxicity in mice. 
Additionally thymus, spleen, bone marrow and PBMCs were collected at 
sacrifice, stained for B and T cell markers and analyzed with the use of flow 
cytometry. We did not observe any significant differences in expression of CD19, 
CD25 or CD138 markers (data not shown) which demonstrate the absence of long 
term effects on the adaptive immune system. 
 
7.2.5 Conclusions and future prospects 
Overall, this study shows that a poly-therapy combining Bortezomib with an 
anti-CD20 monoclonal antibody was not sufficient to lower a high titer of pre-existing 
antibodies against the AAV1 capsid to a level that will enable an efficient AAV1 re-
administration. The same drugs alone or in combination were, by contrast, efficient in 
preventing immune response against the immunogenic protein (OVA) delivered as a 
transgene by AAV1. This observation can be related to the differences in the kinetic 
and mechanism of development of the humoral immune response against the AAV 
capsid and the transgene product delivered by AAV (337). 
The two immunosuppressive agents used in this study, Bortezomib and anti-
CD20, are mainly targeting pre-B cells, mature B cells and memory B cells (179;180). 
Additional cellular inhibitors, as T cell inhibitors, may be required in order to bring 
down the humoral response to the AAV1 capsid. Further studies are needed in order 
to evaluate the efficacy of combination treatment that targets both B and T cells 
population as well as the therapeutic benefit in relation to different nAb levels.  
 




7.3 Materials & methods  
 
7.3.1 Study Design 
C57BL/6 mice (males, age 6-8 weeks) were obtained from Harlan 
Laboratories, the Netherlands (n=6 per group). The experimental protocol was 
approved by the ethical committee for animal welfare of the AMC (Academic 
Medical Center, Amsterdam, the Netherlands). The general procedure is summarized 
in Figure 7.1. Mice received intramuscular injection of AAV1 (CMV-OVA) at day 0, 
at 1x1013gc/kg or PBS/5% sucrose. Blood was drawn weekly and at sacrifice. 
Treatment was initiated with three different experimental regiments. A group 
receiving mono-therapy with Bortezomib (Velcade, company ) at day 28, 33 and 36, a 
group receiving mono-therapy with anti-CD20 antibody (eBioscience, clone: 
AISB12) at day 22 and 27,  a group receiving poly-therapy with both Bortezomib 
(day 28, 33 and 36) and anti-CD20 (Day 22 and 27). Anti-CD20 was administered 
intraperitoneal at 100μg/mouse; Bortezomib was administered intravenously at 
0.75mg/kg. The control groups were mice injected with PBS and mice injected with 
AAV1 (CMV-OVA) only.  
 
7.3.2 AAV vector production and characterization 
AAV vectors were produced (technology adapted from A. Negrete and R.M. 
Kotin (294)) containing  the OVA protein, under the control of the cytomegalovirus 
(CMV) promoter . AAV was purified with an anion column using the ÄKTAexplorer 
system (GE-Healthcare). After purification, presence of AAV capsid proteins (VP1, 
VP2 and VP3) was determined by polyacrylamide gel electrophoresis and 
concentration of vector genomes (gc/ml) determined by qPCR. 
 
7.3.3 Virus neutralizing assay 
HEK293 cells were seeded in a 96 wells plate (Corning) coated with 0.25% 
poly L-lysine at a density of 1 x105cells/well in 100μl DMEM with 10% FBS and 
antibiotics (Penicillin/Streptomycin Solution). Cells were incubated overnight at 
37°C. Medium was then removed and the following mix was added: AAV1 (CMV-
eGFP) incubated with heat-inactivated plasma sample in a total volume of 100μl of 
DMEM with antibiotics. The mix was kept for 1 hour at 4°C before being added. 
Medium of the HEK293 cells was removed by aspiration and the mix added for 20 hr 
at 37°C. Two serial dilutions of test plasma were applied; 1:100, 1:200, 1:400, 1:800, 
1:1600, 1:3200, 1:6400, and 1:12800 and 1:10, 1:20, 1:40, 1:80, 1:160, 1:320, 1:640, 
and 1:1280. As a positive control, cells without plasma were analyzed. The cells were 
washed with PBS and collected after trypsinisation. GFP expression of the cells was 
analyzed by fluorescence-activated cell sorting (FACScalibur, Becton Dickinson) in 
channel FL1 at a wavelength of 530 nm. The analysis was performed with the 
Cellquest software. The percentage of inhibition was calculated related to GFP 
expression measured in rAAV1 HEK293 infected cells (no inhibition, 100% 
expression).  
Plasma samples were considered to have neutralizing activity if the lowest 
plasma dilution inhibited vector transduction by at least 50%, as described before 
(170-172;311).  
  




7.3.4 Assessment of anti-OVA antibody level  
Level of anti-OVA antibody in mouse plasma was measured by anti-OVA 
specific ELISA. Nunc MaxiSorp® flat-bottom 96-well plates (ThermoScientific) were 
coated with 0.5 μg/ml OVA protein and anti-OVA antibody level in samples was 
detected with 1:1000 rabbit-anti-mouse-HRP (DAKO).    
 
7.3.5 Statistical analysis 
Results are presented as means (+/-standard error of the mean (SEM). 
Statistical analyses were performed using Prism 5.0 (GraphPad). Data were analyzed 
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8.1 Summarizing discussion 
The major achievements reported in this thesis are the identification of two 
novel anti-inflammatory approaches with the capacity to ameliorate the intestinal 
inflammatory response and to restore mucosal immune tolerance. Additionally, in 
order to establish the bases of an AAV-based gene therapy approach to treat IBD, 
three complementary studies were performed.  
First, in order to define the AAV serotype of choice for therapy, the pre-
existing nAb titer prevalence to the AAV serotypes -1, -2, -3, -4, -5, -6 and -8 in IBD 
patients was determined. Furthermore, an experimental in vivo model to explore the 
impact of pre-existing nAb titers on AAV transduction was developed. Finally, in 
relation with drug re-administration, immunosuppressive regimens were tested for 
their potential to reduce the humoral immunogenicity generated after primary AAV 
vector gene delivery. 
Part I of this thesis covers the pre-clinical development of a cell therapy based 
treatment for IBD. Chapter 2 and 3, describe a new methodology to generate iTreg 
cells from both murine and human naïve (CD4+CD25-) T cells in vitro. This method 
consists of a two-step activation procedure with an initial PMA/ionomycin activation 
step followed by anti-CD3 stimulation in presence of a low dose of IL-2. By making 
use of substances that are well known, simple to obtain and relatively low priced this 
protocol has the potential to be easily implemented in a routine laboratory setting. 
Long term phenotype stability and functionality of the generated human iTreg cells 
were demonstrated in vitro by use of flow cytometry techniques and mixed 
lymphocyte reactions, respectively. The functionality of the generated murine iTreg 
cells was assessed in vivo, in the Inflammatory Bowel Disease model- CD45RBhigh 
transfer model. Based on the information acquired, the focus of the research was 
shifted to a direct in vivo approach, which is discussed in part II of the thesis.  
Part II covers the development of an AAV based gene therapy approach for 
the treatment of IBD. Chapter 4 describes a study which determined the prevalence 
and titer of pre-existing anti-AAV neutralizing antibodies (nAb) for serotypes -1, -2, -
3, -4, -5, -6 and -8 in a representative panel of IBD patients and healthy controls. 
These data constitute a basis for future AAV-based gene therapies as novel treatment 
approaches for IBD. With those data, AAV5 was shown to have a favorable pre-
existing humoral immune status and could be considered in a gene therapy approach 
in the IBD patient population. Thereafter the purpose was to develop an AAV based 
delivery technique of a protein with the property to induce the activity of endogenous 
Treg cells, for the treatment of IBD. For this purpose regulatory T-cell epitopes 
(Tregitope) were chosen. Tregitope are found in the Fc region of IgG molecules that 
have been shown to have the property to induce the activity of the body’s own Treg 
cells (211;307). In chapter 5 the potential of the Tregitope 167 (211;307) was 
explored for this purpose. Systemic administration of AAV5 (CMV-Tregitope 167) 
was shown to ameliorate the clinical and histopathologic severity of the induced 
inflammatory colitis. The therapeutic effect was associated with an increase in 
expression of the regulatory T cell markers Foxp3 and GARP in the thymic CD4+ 
lymphocyte population. Overall, this study identifies AAV-mediated delivery of 
regulatory T-cell epitope 167 as a novel anti-inflammatory approach with the capacity 
to decrease intestinal inflammation and induce long-term remission in IBD. Based on 
the information acquired, the focus on methodology allowing the induction of iTreg 
and the activation of naturally occurring Treg (nTreg) cells in vivo is the more 
favourable approach for the treatment of IBD. A direct in vivo approach has the 
advantage to be more physiological and could be a more efficient strategy for the 
therapeutic use of Treg cells. 




Part III covers drug re-administration and therefore, immunosuppressive 
regimens were tested for their potential to reduce the humoral immunogenicity 
generated after primary AAV vector gene delivery. Chapter 6 and 7 described in more 
detail the role of neutralizing antibodies in vivo on AAV vector transduction potential 
and strategies to lower this titer of nAbs against the AAV capsid. Chapter 6 details 
the development of an experimental model for in vivo passive transfer of plasma 
containing defined titer of anti-AAV nAbs. Chapter 7 describes the use of three 
immunosuppressive agents to reduce humoral immunogenicity generated by primary 
AAV vector gene delivery. This study demonstrated that a poly-therapy combining 
Bortezomib with an anti-CD20 monoclonal antibody was not sufficient to lower a 
high titer of pre-existing antibodies against the AAV1 capsid to a level that will 
enable an efficient AAV1 re-administration. Therefore novel strategies will need to be 
explored in the future.  




8.2 Future plans and prospects 
In summary, the studies described in this thesis identified two novel anti-
inflammatory strategies with the capacity to ameliorate the intestinal inflammatory 
response and restore mucosal immune tolerance. As an in vitro approach, an 
activation protocol to promote the conversion of naive T cells to a high number of 
functional iTreg was developed. As an in vivo alternative approach, the potential of 
regulatory T-cell epitopes (Tregitopes) found in the Fc region of IgG molecule to 
induce Treg cells in vivo upon delivery by an AAV vector was explored. Based on the 
information acquired, the focus on methodology allowing the induction of iTreg and 
the activation of naturally occurring Treg (nTreg) cells in vivo is the more favourable 
approach for the treatment of IBD. In vitro cell manipulation will not be necessary 
and thereby a direct in vivo approach has the advantage to be more physiological and 
will be a more efficient strategy for the therapeutic use of Treg cells. The success of 
Tregitopes in suppressing experimental autoimmunity can lead to their use as a 
therapy for IBD.   
Strategies to optimize gene therapy approaches include the use of a tissue 
specific promoter enabling site specific expression of a transgene (1). Recently, gut 
specific promoters have been described (338-340). Among those the A33-antigen 
promoter (338;340) which is a promising candidate to induce intestine specific 
expression of a transgene (340). 
Additionally, applying a superior mesenteric artery (SMA) administration 
technique to target the gut directly with the AAV5 vector is promising. SMA injection 
is performed clinically through interventional radiology and thus has translational 
potential. AAV based gene therapy targeting the gut with SMA injections has 
successfully been performed (48;96;341), supporting the possibility to directly target 
the small intestine and colon.  
Inducing local tolerance in the gut while preserving systemic immunity against 
pathogens can be possible using a targeted AAV-mediated delivery of Tregitopes. 
Using the A33-antigen promoter (338;340) and SMA injections for specifically 
targeting the small intestine and colon (48;96;341) will permit the local delivery of 
the Tregitope while maintaining the general immunity against pathogens and tumor 
cells.  
Overall, the studies described in this thesis provide pre-clinical insight into 
novel gene and cell therapy based treatment strategies for the treatment of IBD. 
Additionally these findings were placed in the context of current work in the field and 
thereby describe to possible clinical translational potential of these approaches.  
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9.1 Inflammatoire darmziekten (IBD) 
De Inflammatoire darmziekten (IBD), de ziekte van Crohn en colitis ulcerosa 
zijn beide chronische ontstekingen van het maag-darmkanaal. IBD hebben een grote 
impact op het leven van de patiënt. Beide ziekten hebben zowel acute symptomen, 
zoals buikpijn en diarree als lange termijn gevolgen. Deze kunnen ondermeer bestaan 
uit verstoppingen van de darmen en een vergrote kans op het ontwikkelen van kanker.  
Op het moment bestaat er geen behandeling die patiënten kan genezen. De 
huidige behandelvormen van IBD zijn gericht op het bestrijden van de gevolgen van 
de ziekte maar voor de meeste patiënten is dit niet voldoende om een goede kwaliteit 
van leven te hebben, zoals gezonde personen. Vaak zijn operaties onvermijdelijk. Ook 
hebben veel IBD patiënten last van de bijwerkingen van de nodige medicijnen. Er is 
dientengevolge behoefte aan effectievere behandelvormen.  
Er wordt dan ook aandacht besteed aan de ontwikkeling van nieuwe 
behandelingen die mogelijk op lange termijn wel uitzicht kunnen geven op genezing 
of die de klachten die bij deze ziekten horen kunnen voorkomen en daarmee ook de 
kans op de lange termijn gevolgen van de ziekte kunnen verkleinen. 
 
9.2. Gen- en celtherapie 
 
9.2.1 Gentherapie 
De Centrale Commissie Mensgebonden Onderzoek (CCMO), houdt in 
Nederland toezicht op onderzoek bij patiënten. De CCMO heeft een definitie 
opgesteld voor wat gentherapie inhoud. Onder ‘geneesmiddel voor gentherapie 
verstaat het CCMO een geneesmiddel dat is verkregen door een reeks 
fabricageprocedés gericht op de in vivo of ex vivo overdracht van een profylactisch, 
diagnostisch of therapeutisch gen (een gedeelte van DNA, dat een bepaald eiwit 
codeert) naar menselijke of dierlijke cellen en de erop volgende expressie in vivo. Bij 
de genoverdracht vindt de expressie plaats met behulp van een toedieningsysteem, een 
zogenoemde vector, die een virale of niet-virale oorsprong kan hebben’. 
Anders gesteld, gentherapie zoals beschreven in dit proefschrift, is het 
inbrengen van genetisch materiaal in specifieke cellen van een patiënt, met als doel 
deze cellen te veranderen zodat een bepaald eiwit wordt geproduceerd dat voordelige 
effecten heeft voor de patiënt. Het proces van het overbrengen van een gen kan op 
verschillende manieren worden bewerkstelligd. Voor het in dit proefschrift 
beschreven onderzoek werd voor dit doel gebruik gemaakt van virussen. Het 
toepassen van virussen in de geneeskunde klinkt gevaarlijk, omdat het doel altijd de 
bestrijding van virussen is geweest. Echter, de virussen die voor gentherapie worden 
gebruikt zijn onschadelijk gemaakt. Zo is voor het onderzoek, zoals beschreven in dit 
proefschrift, gebruik gemaakt van de adeno-geassocieerde virussen (AAV). Deze 
virussen kunnen zich niet zelfstandig vermenigvuldigen, veroorzaken geen ziekte en 
zijn dientengevolge, voor het gebruik bij het overbrengen van genetisch materiaal 
relatief veilig.  
  Een geschikte toepassing van gentherapie in IBD omvat het overbrengen van 
genetisch materiaal naar de IBD patiënt, bij voorkeur specifiek de cellen van de 
organen waar ziekteactiviteit verwacht kan worden, waardoor eiwitten worden 
aangemaakt die de ontsteking in de darm kunnen remmen of zelfs voorkomen. 
Hierdoor zou in theorie zowel de acute symptomen van de patiënt, zoals diarree en 
buikpijn worden weggenomen, alsmede de lange termijn risico’s, zoals obstructie en 
een verhoogd risico op kanker kunnen worden verhinderd. 
 
9.2.2 Celtherapie 




De CCMO heeft ook een definitie voor celtherapie opgesteld. Onder 
celtherapie wordt verstaan ‘het toedienen van humane (autologe of allogene), of 
xenogene levende kernhoudende cellen aan de mens waarbij tijdens de isolatie, 
bewerking en/of toediening sprake is van losse individuele levende cellen’.  
De celtherapie die het in dit proefschrift verschenen onderzoek tot doel heeft 
omvat het toedienen van levende cellen aan patiënten als nieuwe methode om IBD te 
behandelen.  
Recent is er onderzoek gestart naar de effectiviteit van de behandeling van 
IBD met mesenchymale stamcellen. Deze lichaamseigen cellen blijken krachtige 
ontstekingsremmende eigenschappen te bezitten. De eerste resultaten van het 
onderzoek zijn veelbelovend en hebben de weg vrijgemaakt om andere vormen van 
celtherapie in IBD te onderzoeken. Het onderzoek beschreven in dit proefschrift richt 
zich op het gebruik van zogenaamde regulatoire T cellen.  
Het menselijke immuunsysteem is zeer succesvol in het bestrijden van 
ziekteverwekkers zoals bacteriën. Het immuunsysteem beschikt over cellen die in 
staat zijn bacteriën en andere micro-organisme aan te vallen, te vernietigen en op te 
ruimen. Men zou deze cellen als een leger kunnen zien die het lichaam verdedigen 
tegen indringers van buiten af. Er zijn echter ook vredestichters nodig die instaat zijn 
datgene te herkennen dat geen kwaad in de zin heeft en dus niet aangevallen dient te 
worden. Daarvoor heeft het menselijk immuunsysteem de net genoemde regulatoire T 
cellen ter beschikking. Deze cellen stoppen of remmen het ontstekingsmechanisme en 
voorkomen dat het immuunsysteem de aanval opent op lichaamseigen structuren of 
nuttige bacteriën in de darm, de zogenoemde darmflora. In IBD zijn deze 
immunologische processen verstoord en daarom is het theoretisch mogelijk het 
evenwicht te herstellen door een patiënt te behandelen met regulatoire T cellen. In de 
vorm van een celtherapeutische aanpak.  
  
Hoofdstuk 1 geeft een algemeen overzicht van de huidige stand van zaken in 
het onderzoek naar gen-, en celtherapeutisch behandelingen in IBD. Het onderzoek 
naar gentherapie in IBD bevindt zich in een experimentele fase en er is nog geen 
onderzoek gedaan bij patiënten. Voor celtherapie is er, voor het gebruik van 
mesenchymale stamcellen in de behandeling van IBD wel mensgebonden onderzoek 
verricht, al valt dit celtype buiten het bereik van dit proefschrift. Deel I van dit 
proefschrift richt zich op de ontwikkeling van een celtherapeutisch behandeling voor 
IBD en Deel II op de ontwikkeling van een gentherapeutisch behandeling voor IBD. 
Hoofdstuk 2 en 3 beschrijven de ontwikkeling van een nieuwe methode die het 
produceren van regulatoire T cellen in het laboratorium mogelijk maakt. Hoe deze 
cellen succesvol konden worden ingezet om ontsteking van de darm te verminderen in 
een experimenteel model van IBD informeert Hoofdstuk 3.  
Hoofdstuk 4, beschrijft een studie naar het voorkomen van antilichamen tegen 
de adeno-geassocieerde virussen (AAV) in een groep van IBD patiënten en gezonde 
vrijwilligers. Dit onderzoek was van belang, omdat in kaart wordt gebracht, welke 
type AAV het beste gebruikt kan worden voor de verdere ontwikkeling van een 
gentherapeutische behandeling voor IBD. Met behulp van deze kennis is een type 
AAV gekozen om genetisch materiaal over te brengen in een experimenteel model 
van IBD. Dit genetische materiaal zorgt ervoor dat er een eiwit wordt aangemaakt dat 
het immuunsysteem kan onderdrukken. Hoofdstuk 5 beschrijft dat met deze AAV 
vector de ontsteking in de darm in dit model kon worden verminderd. Verder wordt 
aangetoond dat in dit experimentele systeem de vermindering van deze ontsteking 
gepaard gaat met een toename van het aantal regulatoire T cellen. Hoofdstuk 6 en 7 
beschrijven in meer detail het belang van antilichamen tegen de AAV vector. Deze 




antilichamen zouden, mogelijkerwijs gentherapie met de AAV minder efficiënt 
kunnen maken. Daarom werd (Hoofdstuk 6) een experimenteel model ontwikkeld 
waarmee de invloed van deze antilichamen kan worden bestudeerd. Er wordt 
aangetoond dat in de muis, antilichamen tegen een AAV, al in hele lage concentraties 
een negatieve invloed hebben op de behandeling met deze AAV. Hoofdstuk 7 
beschrijft een strategie om de aanmaak van deze antilichamen te verminderen. Dit kon 
bewerkstelligd worden met een medicament, te weten Bortezomib, wat specifiek 
antilichaam producerende cellen in het lichaam onschadelijk maakt. Echter, deze 
aanpak was niet voldoende om deze antilichamen geheel te verwijderen en daarom 
dient er in de toekomst verder onderzoek te worden gedaan. Dit onderwerp komt terug 
in Hoofdstuk 8, de algemene discussie van dit proefschrift. Verder wordt in dit 
hoofdstuk commentaar gegeven op noodzaak van vooruitgang in het IBD 
onderzoeksveld dat voor de toekomst gen, en celtherapie mogelijk moet kunnen 
maken.  
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GAA     Acid alpha-glucosidase  
ALCA    Anti-laminaribioside carbohydrate antibody 
AMCA   Anti-mannobioside carbohydrate antibody 
ANCA    Antineutrophil cytoplasmic antibody  
anti-C     Anti-chitin  
anti-L     Anti-laminarin  
APC    Antigen presenting cell 
ASCA,   Anti-Saccharomyces cerevisiae antibodies 
ATP     Adenosine-5'-triphosphate  
QA/QC    Quality assurance/ Quality control 
CCMO    Centrale Commissie Mensgebonden Onderzoek 
CD    Crohn’s disease  
CIDP    Chronic inflammatory demyelinating polyneuropathy  
CMV     Cytomegalovirus  
CRIM     Cross-reactive immunologic material 
CRP    C reactive protein  
CTLA-4    Cytotoxic T-Lymphocyte Antigen 4 
DAI     Disease activity index 
DC    Dentritic cell 
DMEM    Dulbecco’s modified Eagle’s medium  
DNA     Deoxyribonucleic acid 
EAE     Experimental autoimmune encephalomyelitis 
ERT     Enzyme replacement therapy  
Et al.     (Latin, et alii) and others 
Fab     Fragment, antigen binding region  
Fc     Fragment, crystallisable region 
FBS     Fetal bovine serum  
Foxp3    Forkhead Box-P3 
GAA    Alpha-glucosidase 
Gc    Genome copy 
GI     Gastro-intestinal  
GFP     Green fluorescent protein  
GITR     Glucocorticoid-induced TNFR-related protein 
GMP    Good Manufacturing Practices 
HE    Hematoxylin and eosin  
HEK293     Human Embryonic Kidney 293  
HIV     Human immunodeficiency virus 
IBD     Inflammatory bowel diseases  
ICOS     Inducible co-stimulator 
Ig    Immunoglobulin 
IL    Interleukin 
IS    Immuno-suppression 
ITP    Idiopathic thrombocytopenic purpura  
iTreg cell    Induced regulatory T cell  
IVIG    Intravenous immunoglobulin 
Max    Maximum 




MHC    Major Histocompatibility complex  
Min    Minimum 
miRNA   Micro RNA 
MLR    Mixed lymphocyte reaction  
MSC     Mesenchymal stromal cells 
MS     Multiple sclerosis 
MTX     Methotrexate 
nAb    Neutralizing antibody  
NOD/SCID   Non-obese diabetic/severe combined immunodeficiency 
nTreg cells   Naturally occurring regulatory T cell  
OmpC    Outer membrane porin C 
OPG     Osteoprotegerin  
OVA     Ovalbumin  
PAB    Pancreatic auto-antibodies  
PBMC    Peripheral blood mononuclear cell 
PCR     Polymerase Chain Reaction 
PMA     Phorbol-12-myristate-13-acetate 
qPCR     Quantitative Polymerase Chain Reaction 
rAAV     Recombinant adeno-associated viruses 
R&D     Research and Development 
Rh    Recombinant human 
RNA     Ribonucleic acid 
SD     Standard deviation 
SEM    Standard error of the mean 
SLE     Systemic lupus erythematosus  
TCR    T cell receptors  
T1D    Type 1 diabetes 
TNBS     Trinitrobenzene sulfonate 
TNF    Tumor Necrosis Factor 
Teff cell    Effector T cell 
Treg cells    Regulatory T cells 
Tregitope   Regulatory T cell epitope 
TregPMA cells  iTreg cells induced by PMA/ionomycin/antiCD3/IL-2 
UC    Ulcerative colitis  
WPRE    Woodchuck hepatitis virus post-transcriptional enhancer  
Yr    Years 
 
Marel vd_BW (all).ps Back - 68     T1 -    Black CyanMagentaYellow
Gene and cell therapy 
based treatment strategies 
for inflammatory 
bowel diseases
Sander van der Marel
G
ene and cell therapy based treatm
ent strategies for inflam
m
atory bow
el diseases       
Sander van der M
arel
UitnodiGinG
Voor het bijwonen van 
de openbare verdedinging 
van het proefschrift
Gene and cell therapy 




Sander van der Marel





Na afloop van de promotie 
bent u van harte welkom 
op de receptie,
Sander van der Marel
Maresingel 42
2316HC Leiden
Marel vd, Sander_omslag.indd   1 10-12-13   11:56
